



Kongeriget Danmark

Patent application No.: PA 2003 01624

Date of filing: 31 October 2003

Applicant: Novozymes A/S
(Name and address) Krogshøjvej 36
DK-2880 Bagsværd
Denmark

Title: Method for stable gene-amplification in a bacterial host cell

IPC: -

This is to certify that the attached documents are exact copies of the above mentioned patent application as originally filed.



Patent- og Varemærkestyrelsen
Økonomi- og Erhvervsministeriet

28 October 2004

Susanne Morsing
Susanne Morsing

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

TITLE: Method for stable gene-amplification in a bacterial host cell

FIELD OF INVENTION

In the biotech industry it is desirable to construct polypeptide production strains having several copies of a gene of interest stably chromosomally integrated, without leaving antibiotic resistance marker genes in the strains.

This invention relates to bacterial host cells comprising at least two copies of an amplification unit in its genome, said amplification unit comprising: i) at least one copy of a gene of interest, and ii) an expressible conditionally essential gene, wherein the conditionally essential gene is either promoterless or transcribed from a heterologous promoter having an activity substantially lower than the endogenous promoter of said conditionally essential gene, and wherein the conditionally essential gene if not functional would render the cell auxotrophic for at least one specific substance or unable to utilize one or more specific sole carbon source; methods for producing a protein using the cell of the invention, and methods for constructing the cell of the invention.

BACKGROUND OF THE INVENTION

In the industrial production of polypeptides it is of interest to achieve a product yield as high as possible. One way to increase the yield is to increase the copy number of a gene encoding a polypeptide of interest. This can be done by placing the gene on a high copy number plasmid, however plasmids are unstable and are often lost from the host cells if there is no selective pressure during the cultivation of the host cells. Another way to increase the copy number of the gene of interest is to integrate it into the host cell chromosome in multiple copies.

The present day public debate concerning the industrial use of recombinant DNA technology has raised some questions and concerns about the use of antibiotic resistance marker genes. Antibiotic marker genes are traditionally used as a means to select for strains carrying multiple copies of both the marker genes and an accompanying expression cassette coding for a polypeptide of industrial interest. In order to comply with the current demand for recombinant production host strains devoid of antibiotic markers, we have looked for possible alternatives to the present technology that will allow substitution of the antibiotic markers we use today with non-antibiotic marker genes.

WO 02/00907 (Novozymes, Denmark) discloses a method for stable chromosomal multi-copy integration of genes into a production host cell in specific well-defined sites. It is disclosed to first render a recipient cell deficient by inactivating one or more conditionally essential gene, e.g., to make the cell auxotrophic for an amino acid. A gene of interest may then be integrated into the chromosome along with a DNA sequence which complements the

deficiency of the cell cell, thus making the resulting cell selectable; the *Bacillus licheniformis* *metC* gene is disclosed as a conditionally essential marker herein.

WO 01/90393 (Novozymes, Denmark) discloses a method for increasing the gene copy number in a host cell by gene-amplification, without leaving antibiotic resistance markers behind in the host cell. The disclosed method relies on rendering a specific type of conditionally essential chromosomal gene of the host cell non-functional, thereby rendering the cell susceptible to an inhibitory compound produced endogenously by the cell when cultivated in the presence of a precursor. A single amplification unit comprising the gene of interest, and a DNA sequence, which when integrated into the chromosome complements the non-functional conditional essential chromosomal gene, is integrated into the chromosome. This method relies on the endogenous production of an inhibitory compound by the host cell in order to achieve gene amplification in a similar manner as to when classical antibiotic selection markers are used for gene amplification; the presence of the inhibitory compound gives a survival advantage to those cells carrying duplications of the amplification unit.

In order to provide recombinant production strains devoid of antibiotic resistance markers, it remains of industrial interest to find new methods to stably integrate genes in multiple copies into host cell chromosomes. Even incremental improvements of existing methods or mere alternatives are of considerable interest to the industry.

SUMMARY OF THE INVENTION

The problem to be solved by the present invention is to provide alternative host cells comprising multiple copies of a gene of interest, which cells are devoid of antibiotic markers, for use in the industrial production of polypeptides in high yields.

The solution is based on the observation that an amplification unit can be integrated into the chromosome of a host cell, and subsequently be amplified, without the use of classical antibiotic markers, antibiotics, or endogenously produced inhibitory compounds.

In traditional amplification protocols, higher gene expression is a result of duplications of the antibiotic resistance marker gene, duplications which are selected in stepwise cultivation and selection rounds by adding increasing amounts of the antibiotic compound to the cultivation medium in each cultivation step.

A cell which has become auxotrophic, e.g., due to a non-functional conditionally essential gene, would normally be complemented back to the prototrophic phenotype by the integration (or restoration) in the chromosome of even one single functional copy of the non-functional gene. Since normally only one copy is needed, such genes have not previously been attractive candidates for amplification purposes.

However, the present inventors lowered the expression-level of a non-antibiotic conditionally essential gene by decreasing the promoter activity, so that more than one

10442.000-OK

functional copy of the gene would be advantageous to a deficient host cell. The integration of an amplification unit comprising such a low-level expression conditionally essential gene, into a host cell deficient for the same gene, reproducibly resulted in genomic duplications of the integrated amplification unit, comparable to what has been observed when using traditional amplifiable antibiotic markers.

In fact, this invention provides the means for controlling the level of gene expression, i.e., copy-number, in a host cell. By choosing carefully the strength of the heterologous promoter expressing the conditionally essential marker gene in the amplification unit, the optimal copy-number of the amplification unit can be adjusted up or down, depending on the desired expression level of the gene of interest also comprised in the unit.

Accordingly, in a first aspect the invention relates to a bacterial host cell comprising at least two copies of an amplification unit in its genome, said amplification unit comprising:

- i) at least one copy of a gene of interest, and
- ii) an expressible conditionally essential gene, wherein the conditionally essential gene is either promoterless or transcribed from a heterologous promoter having an activity substantially lower than the endogenous promoter of said conditionally essential gene, and

wherein the conditionally essential gene if not functional would render the cell auxotrophic for at least one specific substance or unable to utilize one or more specific sole carbon source.

In a second aspect, the invention relates to a method for producing a protein encoded by a gene of interest, comprising

a) culturing a bacterial host cell comprising at least two duplicated copies of an amplification unit in its genome, the amplification unit comprising:

- i) at least one copy of the gene of interest, and
- ii) an expressible conditionally essential gene, wherein the conditionally essential gene is either promoterless or transcribed from a heterologous promoter having an activity substantially lower than the endogenous promoter of said conditionally essential gene,

wherein the conditionally essential gene if not functional would render the cell auxotrophic for at least one specific substance or unable to utilize one or more specific sole carbon source; and

b) recovering the protein.

In a final aspect, the invention also relates to a method for producing a bacterial cell comprising two or more amplified chromosomal copies of a gene of interest, the method comprising:

a) providing a bacterial cell comprising at least one copy of an amplification unit, the unit comprising:

10442.000-DK

- i) at least one copy of the gene of interest, and
- ii) an expressible functional copy of a conditionally essential gene, which is either promoterless or transcribed from a heterologous promoter having an activity substantially lower than the endogenous promoter of said conditionally essential gene,

wherein the conditionally essential gene if not functional would render the cell auxotrophic for at least one specific substance or unable to utilize one or more specific sole carbon source;

- c) cultivating the cell under conditions suitable for growth in a medium deficient of said at least one specific substance and/or with said one or more specific sole carbon source, thereby providing a growth advantage to a cell in which the amplification unit has been duplicated in the chromosome; and
- c) selecting a cell wherein the amplification unit has been duplicated in the chromosome, whereby two or more amplified chromosomal copies of the gene of interest were produced.

It is envisioned that all the preferred embodiments of the cell of the invention that are shown herein would be suitable for use in the methods of the second and third aspects of the invention

DEFINITIONS

In accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook, Fritsch & Maniatis, *Molecular Cloning: A Laboratory Manual*, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (herein "Sambrook et al., 1989"); *DNA Cloning: A Practical Approach*, Volumes I and II /D.N. Glover ed. 1985); *Oligonucleotide Synthesis* (M.J. Gait ed. 1984); *Nucleic Acid Hybridization* (B.D. Hames & S.J. Higgins eds (1985)); *Transcription And Translation* (B.D. Hames & S.J. Higgins, eds. (1984)); *Animal Cell Culture* (R.I. Freshney, ed. (1986)); *Immobilized Cells And Enzymes* (IRL Press, (1986)); B. Perbal, *A Practical Guide To Molecular Cloning* (1984).

A "polynucleotide" is a single- or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases read from the 5' to the 3' end. Polynucleotides include RNA and DNA, and may be isolated from natural sources, synthesized in vitro, or prepared from a combination of natural and synthetic molecules.

A "nucleic acid molecule" or "nucleotide sequence" refers to the phosphate ester polymeric form of ribonucleosides (adenosine, guanosine, uridine or cytidine; "RNA molecules") or deoxyribonucleosides (deoxyadenosine, deoxyguanosine, deoxythymidine, or deoxycytidine; "DNA molecules") in either single stranded form, or a double-stranded helix.

Double stranded DNA-DNA, DNA-RNA and RNA-RNA helices are possible. The term nucleic acid molecule, and in particular DNA or RNA molecule, refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary or quaternary forms. Thus, this term includes double-stranded DNA found, inter alia, in linear or circular DNA molecules (e.g., restriction fragments), plasmids, and chromosomes. In discussing the structure of particular double-stranded DNA molecules, sequences may be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand of DNA (i.e., the strand having a sequence homologous to the mRNA). A "recombinant DNA molecule" is a DNA molecule that has undergone a molecular biological manipulation.

A nucleic acid molecule is "hybridizable" to another nucleic acid molecule, such as a cDNA, genomic DNA, or RNA, when a single stranded form of the nucleic acid molecule can anneal to the other nucleic acid molecule under the appropriate conditions of temperature and solution ionic strength (see Sambrook et al., supra). The conditions of temperature and ionic strength determine the "stringency" of the hybridization.

A DNA "coding sequence" or an "open reading frame (ORF)" is a double-stranded DNA sequence which is transcribed and translated into a polypeptide in a cell in vitro or in vivo when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxyl) terminus. A coding sequence can include, but is not limited to, prokaryotic sequences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (e.g., mammalian) DNA, and even synthetic DNA sequences. If the coding sequence is intended for expression in a eukaryotic cell, a polyadenylation signal and transcription termination sequence will usually be located 3' to the coding sequence.

An expression vector is a DNA molecule, linear or circular, that comprises a segment encoding a polypeptide of interest operably linked to additional segments that provide for its transcription. Such additional segments may include promoter and terminator sequences, and optionally one or more origins of replication, one or more selectable markers, an enhancer, a polyadenylation signal, and the like. Expression vectors are generally derived from plasmid or viral DNA, or may contain elements of both.

Transcriptional and translational control sequences are DNA regulatory sequences, such as promoters, enhancers, terminators, and the like, that provide for the expression of a coding sequence in a host cell. In eukaryotic cells, polyadenylation signals are control sequences.

A "secretory signal sequence" is a DNA sequence that encodes a polypeptide (a "secretory peptide" that, as a component of a larger polypeptide, directs the larger polypeptide through a secretory pathway of a cell in which it is synthesized. The larger

polypeptide is commonly cleaved to remove the secretory peptide during transit through the secretory pathway.

5 The term "promoter" is used herein for its art-recognized meaning to denote a portion of a gene containing DNA sequences that provide for the binding of RNA polymerase and initiation of transcription. Promoter sequences are commonly, but not always, found in the 5' non-coding regions of genes.

10 A chromosomal gene is rendered non-functional if the polypeptide that the gene encodes can no longer be expressed in a functional form. Such non-functionality of a gene can be induced by a wide variety of genetic manipulations as known in the art, some of which are described in Sambrook et al. vide supra. Partial deletions within the ORF of a gene will often render the gene non-functional, as will mutations.

15 The term "an expressible copy of a chromosomal gene" is used herein as meaning a copy of the ORF of a chromosomal gene, wherein the ORF can be expressed to produce a fully functional gene product. The expressible copy may not be transcribed from the native promoter of the chromosomal gene, it may instead be transcribed from a foreign or heterologous promoter, or it may indeed be promoterless and expressed only by transcriptional read-through from a gene present upstream of the 5' end of the ORF. Transcriptional read-through is intended to have the same meaning here as the generally recognized meaning in the art.

20 "Operably linked", when referring to DNA segments, indicates that the segments are arranged so that they function in concert for their intended purposes, e.g. transcription initiates in the promoter and proceeds through the coding segment to the terminator.

25 A coding sequence is "under the control" of transcriptional and translational control sequences in a cell when RNA polymerase transcribes the coding sequence into mRNA, which is then trans-RNA spliced and translated into the protein encoded by the coding sequence.

"Heterologous" DNA refers to DNA not naturally located in the cell, or in a chromosomal site of the cell. Preferably, the heterologous DNA includes a gene foreign to the cell.

30 As used herein the term "nucleic acid construct" is intended to indicate any nucleic acid molecule of cDNA, genomic DNA, synthetic DNA or RNA origin. The term "construct" is intended to indicate a nucleic acid segment which may be single- or double-stranded, and which may be based on a complete or partial naturally occurring nucleotide sequence encoding a polypeptide of interest. The construct may optionally contain other nucleic acid segments.

35 The nucleic acid construct of the invention encoding the polypeptide of the invention may suitably be of genomic or cDNA origin, for instance obtained by preparing a genomic or

10442.000-DK

cDNA library and screening for DNA sequences coding for all or part of the polypeptide by hybridization using synthetic oligonucleotide probes in accordance with standard techniques (cf. Sambrook et al., supra).

5 The nucleic acid construct of the invention encoding the polypeptide may also be prepared synthetically by established standard methods, e.g. the phosphoramidite method described by Beaucage and Caruthers, Tetrahedron Letters 22 (1981), 1859 - 1869, or the method described by Matthes et al., EMBO Journal 3 (1984), 801 - 805. According to the phosphoramidite method, oligonucleotides are synthesized, e.g. in an automatic DNA synthesizer, purified, annealed, ligated and cloned in suitable vectors.

10 Furthermore, the nucleic acid construct may be of mixed synthetic and genomic, mixed synthetic and cDNA or mixed genomic and cDNA origin prepared by ligating fragments of synthetic, genomic or cDNA origin (as appropriate), the fragments corresponding to various parts of the entire nucleic acid construct, in accordance with standard techniques. The nucleic acid construct may also be prepared by polymerase chain
15 reaction using specific primers, for instance as described in US 4,683,202 or Saiki et al., Science 239 (1988), 487 - 491.

The term nucleic acid construct may be synonymous with the term "expression cassette" when the nucleic acid construct contains the control sequences necessary for expression of a coding sequence of the present invention

20 The term "control sequences" is defined herein to include all components which are necessary or advantageous for expression of the coding sequence of the nucleic acid sequence. Each control sequence may be native or foreign to the nucleic acid sequence encoding the polypeptide. Such control sequences include, but are not limited to, a leader, a polyadenylation sequence, a propeptide sequence, a promoter, a signal sequence, and a
25 transcription terminator. At a minimum, the control sequences include a promoter, and transcriptional and translational stop signals. The control sequences may be provided with linkers for the purpose of introducing specific restriction sites facilitating ligation of the control sequences with the coding region of the nucleic acid sequence encoding a polypeptide.

The control sequence may be an appropriate promoter sequence, a nucleic acid
30 sequence which is recognized by a host cell for expression of the nucleic acid sequence. The promoter sequence contains transcription and translation control sequences which mediate the expression of the polypeptide. The promoter may be any nucleic acid sequence which shows transcriptional activity in the host cell of choice and may be obtained from genes encoding extracellular or intracellular polypeptides either homologous or
35 heterologous to the host cell.

The control sequence may also be a suitable transcription terminator sequence, a sequence recognized by a host cell to terminate transcription. The terminator sequence is

operably linked to the 3' terminus of the nucleic acid sequence encoding the polypeptide. Any terminator which is functional in the host cell of choice may be used in the present invention.

The control sequence may also be a polyadenylation sequence, a sequence which is operably linked to the 3' terminus of the nucleic acid sequence and which, when transcribed, is recognized by the host cell as a signal to add polyadenosine residues to transcribed mRNA. Any polyadenylation sequence which is functional in the host cell of choice may be used in the present invention.

The control sequence may also be a signal peptide coding region, which codes for an amino acid sequence linked to the amino terminus of the polypeptide which can direct the expressed polypeptide into the cell's secretory pathway of the host cell. The 5' end of the coding sequence of the nucleic acid sequence may inherently contain a signal peptide coding region naturally linked in translation reading frame with the segment of the coding region which encodes the secreted polypeptide. Alternatively, the 5' end of the coding sequence may contain a signal peptide coding region which is foreign to that portion of the coding sequence which encodes the secreted polypeptide. A foreign signal peptide coding region may be required where the coding sequence does not normally contain a signal peptide coding region. Alternatively, the foreign signal peptide coding region may simply replace the natural signal peptide coding region in order to obtain enhanced secretion of the [enzyme] relative to the natural signal peptide coding region normally associated with the coding sequence. The signal peptide coding region may be obtained from a glucoamylase or an amylase gene from an *Aspergillus* species, a lipase or proteinase gene from a *Rhizomucor* species, the gene for the alpha-factor from *Saccharomyces cerevisiae*, an amylase or a protease gene from a *Bacillus* species, or the calf preprochymosin gene. However, any signal peptide coding region capable of directing the expressed polypeptide into the secretory pathway of a host cell of choice may be used in the present invention.

The control sequence may also be a propeptide coding region, which codes for an amino acid sequence positioned at the amino terminus of a polypeptide. The resultant polypeptide is known as a proenzyme or propolypeptide (or a zymogen in some cases). A propolypeptide is generally inactive and can be converted to mature active polypeptide by catalytic or autocatalytic cleavage of the propeptide from the propolypeptide. The propeptide coding region may be obtained from the *Bacillus subtilis* alkaline protease gene (aprE), the *Bacillus subtilis* neutral protease gene (nprT), the *Saccharomyces cerevisiae* alpha-factor gene, or the *Myceliophthora thermophilum* laccase gene (WO 95/33836).

It may also be desirable to add regulatory sequences which allow the regulation of the expression of the polypeptide relative to the growth of the host cell. Examples of regulatory systems are those which cause the expression of the gene to be turned on or off in response to a chemical or physical stimulus, including the presence of a regulatory

10442.000-DK

compound. Regulatory systems in prokaryotic systems would include the lac, tac, and trp operator systems. In yeast, the ADH2 system or GAL1 system may be used. In filamentous fungi, the TAKA alpha-amylase promoter, *Aspergillus niger* glucoamylase promoter, and the *Aspergillus oryzae* glucoamylase promoter may be used as regulatory sequences. Other examples of regulatory sequences are those which allow for gene amplification. In eukaryotic systems, these include the dihydrofolate reductase gene which is amplified in the presence of methotrexate, and the metallothionein genes which are amplified with heavy metals. In these cases, the nucleic acid sequence encoding the polypeptide would be placed in tandem with the regulatory sequence.

Examples of suitable promoters for directing the transcription of the conditionally essential gene(s) of the present invention, especially in a bacterial host cell, are the promoters obtained from the *E. coli* lac operon, the *Streptomyces coelicolor* agarase gene (dagA), the *Bacillus subtilis* levansucrase gene (sacB), the *Bacillus subtilis* alkaline protease gene, the *Bacillus licheniformis* alpha-amylase gene (amyL), the *Bacillus stearothermophilus* maltogenic amylase gene (amyM), the *Bacillus amyloliquefaciens* alpha-amylase gene (amyQ), the *Bacillus amyloliquefaciens* BAN amylase gene, the *Bacillus licheniformis* penicillinase gene (penP), the *Bacillus subtilis* xylA and xylB genes, and the prokaryotic beta-lactamase gene (Villa-Komaroff et al., 1978, Proceedings of the National Academy of Sciences USA 75:3727-3731), as well as the tac promoter (DeBoer et al., 1983, Proceedings of the National Academy of Sciences USA 80:21-25). Further promoters are described in "Useful proteins from recombinant bacteria" in Scientific American, 1980, 242:74-94; and in Sambrook et al., 1989, supra.

The term "auxotrophic" in the present context means that the auxotrophic cell requires at least one specific substance for growth and metabolism that the parental organism was able to synthesize on its own. The term is used with respect to organisms, such as strains of bacteria, that can no longer synthesize the substance(s) because of mutational changes.

An effective signal peptide coding region for bacterial host cells is the signal peptide coding region obtained from the maltogenic amylase gene from *Bacillus* NCIB 11837, the *Bacillus stearothermophilus* alpha-amylase gene, the *Bacillus licheniformis* subtilisin gene, the *Bacillus licheniformis* beta-lactamase gene, the *Bacillus stearothermophilus* neutral proteases genes (nprT, nprS, nprM), and the *Bacillus subtilis* PrsA gene. Further signal peptides are described by Simonen and Palva, 1993, Microbiological Reviews 57:109-137.

The present invention also relates to recombinant expression vectors comprising a nucleic acid sequence of the present invention, a promoter, and transcriptional and translational stop signals. The various nucleic acid and control sequences described above may be joined together to produce a recombinant expression vector which may include one or more convenient restriction sites to allow for insertion or substitution of the nucleic acid

sequence encoding the polypeptide at such sites. Alternatively, the nucleic acid sequence of the present invention may be expressed by inserting the nucleic acid sequence or a nucleic acid construct comprising the sequence into an appropriate vector for expression. In creating the expression vector, the coding sequence is located in the vector so that the coding sequence is operably linked with the appropriate control sequences for expression, and possibly secretion.

The recombinant expression vector may be any vector (e.g., a plasmid or virus) which can be conveniently subjected to recombinant DNA procedures and can bring about the expression of the nucleic acid sequence. The choice of the vector will typically depend on the compatibility of the vector with the host cell into which the vector is to be introduced. The vectors may be linear or closed circular plasmids. The vector may be an autonomously replicating vector, i.e., a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g., a plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome. The vector may contain any means for assuring self-replication. Alternatively, the vector may be one which, when introduced into the host cell, is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated. The vector system may be a single vector or plasmid or two or more vectors or plasmids which together contain the total DNA to be introduced into the genome of the host cell, or a transposon.

The vectors of the present invention preferably contain one or more selectable markers which permit easy selection of transformed cells. A selectable marker is a gene the product of which provides for biocide or viral resistance, resistance to heavy metals, prototrophy to auxotrophs, and the like.

Antibiotic selectable markers confer antibiotic resistance to such antibiotics as ampicillin, kanamycin, chloramphenicol, tetracycline, neomycin, hygromycin or methotrexate. Suitable markers for yeast host cells are ADE2, HIS3, LEU2, LYS2, MET3, TRP1, and URA3.

The vectors of the present invention preferably contain an element(s) that permits stable integration of the vector, or of a smaller part of the vector, into the host cell genome or autonomous replication of the vector in the cell independent of the genome of the cell.

The vectors, or smaller parts of the vectors such as amplification units of the present invention, may be integrated into the host cell genome when introduced into a host cell. For chromosomal integration, the vector may rely on the nucleic acid sequence encoding the polypeptide or any other element of the vector for stable integration of the vector into the genome by homologous or nonhomologous recombination.

Alternatively, the vector may contain additional nucleic acid sequences for directing integration by homologous recombination into the genome of the host cell. The additional nucleic acid sequences enable the vector to be integrated into the host cell genome at a

precise location(s) in the chromosome(s). To increase the likelihood of integration at a precise location, the integrational elements should preferably contain a sufficient number of nucleic acids, such as 100 to 1,500 base pairs, preferably 400 to 1,500 base pairs, and most preferably 800 to 1,500 base pairs, which are highly homologous with the corresponding target sequence to enhance the probability of homologous recombination. The integrational elements may be any sequence that is homologous with the target sequence in the genome of the host cell. Furthermore, the integrational elements may be non-encoding or encoding nucleic acid sequences; specific examples of encoding sequences suitable for site-specific integration by homologous recombination are given in WO 02/00907 (Novozymes, Denmark), which is hereby incorporated by reference in its totality.

On the other hand, the vector may be integrated into the genome of the host cell by non-homologous recombination. These nucleic acid sequences may be any sequence that is homologous with a target sequence in the genome of the host cell, and, furthermore, may be non-encoding or encoding sequences. The copy number of a vector, an expression cassette, an amplification unit, a gene or indeed any defined nucleotide sequence is the number of identical copies that are present in a host cell at any time. A gene or another defined chromosomal nucleotide sequence may be present in one, two, or more copies on the chromosome. An autonomously replicating vector may be present in one, or several hundred copies per host cell.

An amplification unit of the invention is a nucleotide sequence that can integrate into the chromosome of a host cell, whereupon it can increase in number of chromosomally integrated copies by duplication or multiplication. The unit comprises an expression cassette as defined herein comprising at least one copy of a gene of interest and an expressible copy of a chromosomal gene, as defined herein, of the host cell. When the amplification unit is integrated into the chromosome of a host cell, it is defined as that particular region of the chromosome which is prone to being duplicated by homologous recombination between two directly repeated regions of DNA. The precise border of the amplification unit with respect to the flanking DNA is thus defined functionally, since the duplication process may indeed duplicate parts of the DNA which was introduced into the chromosome as well as parts of the endogenous chromosome itself, depending on the exact site of recombination within the repeated regions. This principle is illustrated in Janniére *et al.* (1985, Stable gene amplification in the chromosome of *Bacillus subtilis*. Gene, 40: 47-55), which is incorporated herein by reference.

For autonomous replication, the vector may further comprise an origin of replication enabling the vector to replicate autonomously in the host cell in question. Examples of bacterial origins of replication are the origins of replication of plasmids pBR322, pUC19, pACYC177, pACYC184, pUB110, pE194, pTA1060, and pAMBeta1. Examples of origin of replications for use in a yeast host cell are the 2 micron origin of replication, the combination

of CEN6 and ARS4, and the combination of CEN3 and ARS1. The origin of replication may be one having a mutation which makes its functioning temperature-sensitive in the host cell (see, e.g., Ehrlich, 1978, Proceedings of the National Academy of Sciences USA 75:1433).

The present invention also relates to recombinant host cells, comprising a nucleic acid sequence of the invention, which are advantageously used in the recombinant production of the polypeptides. The term "host cell" encompasses any progeny of a parent cell which is not identical to the parent cell due to mutations that occur during replication.

The cell is preferably transformed with a vector comprising a nucleic acid sequence of the invention followed by integration of the vector into the host chromosome.

"Transformation" means introducing a vector comprising a nucleic acid sequence of the present invention into a host cell so that the vector is maintained as a chromosomal integrant or as a self-replicating extra-chromosomal vector. Integration is generally considered to be an advantage as the nucleic acid sequence is more likely to be stably maintained in the cell. Integration of the vector into the host chromosome may occur by homologous or non-homologous recombination as described above.

The transformation of a bacterial host cell may, for instance, be effected by protoplast transformation (see, e.g., Chang and Cohen, 1979, Molecular General Genetics 168:111-115), by using competent cells (see, e.g., Young and Spizizin, 1961, Journal of Bacteriology 81:823-829, or Dubnar and Davidoff-Abelson, 1971, Journal of Molecular Biology 56:209-221), by electroporation (see, e.g., Shigekawa and Dower, 1988, Biotechniques 6:742-751), or by conjugation (see, e.g., Koehler and Thorne, 1987, Journal of Bacteriology 169:5771-5278).

The transformed or transfected host cells described above are cultured in a suitable nutrient medium under conditions permitting the expression of the desired polypeptide, after which the resulting polypeptide is recovered from the cells, or the culture broth.

The medium used to culture the cells may be any conventional medium suitable for growing the host cells, such as minimal or complex media containing appropriate supplements. Suitable media are available from commercial suppliers or may be prepared according to published recipes (e.g. in catalogues of the American Type Culture Collection). The media are prepared using procedures known in the art (see, e.g., references for bacteria and yeast; Bennett, J.W. and LaSure, L., editors, More Gene Manipulations in Fungi, Academic Press, CA, 1991).

If the polypeptide is secreted into the nutrient medium, the polypeptide can be recovered directly from the medium. If the polypeptide is not secreted, it is recovered from cell lysates. The polypeptide are recovered from the culture medium by conventional procedures including separating the host cells from the medium by centrifugation or filtration, precipitating the proteinaceous components of the supernatant or filtrate by means of a salt, e.g. ammonium sulphate, purification by a variety of chromatographic procedures, e.g. ion

10442.000-DK

exchange chromatography, gel filtration chromatography, affinity chromatography, or the like, dependent on the type of polypeptide in question.

The polypeptides may be detected using methods known in the art that are specific for the polypeptides. These detection methods may include use of specific antibodies, formation of an enzyme product, or disappearance of an enzyme substrate. For example, an enzyme assay may be used to determine the activity of the polypeptide.

The polypeptides of the present invention may be purified by a variety of procedures known in the art including, but not limited to, chromatography (e.g., ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures (e.g., preparative isoelectric focusing (IEF), differential solubility (e.g., ammonium sulfate precipitation), or extraction (see, e.g., Protein Purification, J.-C. Janson and Lars Ryden, editors, VCH Publishers, New York, 1989).

DETAILED DESCRIPTION OF THE INVENTION

The first aspect of the invention relates to a bacterial host cell comprising at least two copies of an amplification unit in its genome, said amplification unit comprising:

- i) at least one copy of a gene of interest, and
- ii) an expressible conditionally essential gene, wherein the conditionally essential gene is either promoterless or transcribed from a heterologous promoter having an activity substantially lower than the endogenous promoter of said conditionally essential gene, and

wherein the conditionally essential gene if not functional would render the cell auxotrophic for at least one specific substance or unable to utilize one or more specific sole carbon source.

The choice of a host cell will to a large extent depend upon the gene encoding the polypeptide and its source. The host cell may be a unicellular microorganism, e.g., a prokaryote, or a non-unicellular microorganism, e.g., a eukaryote. Useful unicellular cells are bacterial cells such as gram positive bacteria including, but not limited to, a *Bacillus* cell, e.g., *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus brevis*, *Bacillus circulans*, *Bacillus coagulans*, *Bacillus lautus*, *Bacillus lentus*, *Bacillus licheniformis*, *Bacillus megaterium*, *Bacillus stearothermophilus*, *Bacillus subtilis*, and *Bacillus thuringiensis*; or a *Streptomyces* cell, e.g., *Streptomyces lividans* or *Streptomyces murinus*, or gram negative bacteria such as *E. coli* and *Pseudomonas sp.* In a preferred embodiment, the bacterial host cell is a *Bacillus lentus*, *Bacillus licheniformis*, *Bacillus stearothermophilus* or *Bacillus subtilis* cell. In one preferred embodiment, the bacterial host cell is a prokaryotic cell, preferably a Gram-positive prokaryotic cell, and more preferably the bacterial Gram positive cell is a species of the genus *Bacillus*, preferably selected from the group consisting of *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus brevis*, *Bacillus circulans*,

Bacillus coagulans, Bacillus lautus, Bacillus lentus, Bacillus licheniformis, Bacillus megaterium, Bacillus stearothermophilus, Bacillus subtilis, and Bacillus thuringiensis.

As described above, chromosomal integration of a vector or a smaller part of a vector, such as an amplification unit of the invention, into the genome of the host cell can be achieved by a number of ways. A non-limiting example of integration by homologous recombination is shown herein.

A preferred embodiment of the invention relates to the cells of the invention, or the methods of the invention, wherein the amplification unit further comprises a nucleotide sequence with a homology to a chromosomal nucleotide sequence of the host cell sufficient to effect chromosomal integration in the host cell of the amplification unit by homologous recombination, preferably the amplification unit further comprises a nucleotide sequence of at least 100 bp, preferably 200 bp, more preferably 300 bp, even more preferably 400 bp, and most preferably at least 500 bp with an identity of at least 70%, preferably 80%, more preferably 90%, even more preferably 95%, and most preferably at least 98% identity to a chromosomal nucleotide sequence of the host cell.

In a non-limiting example integration into the chromosome of a host cell can be selected for by first rendering a conditionally essential host cell gene non-functional as described elsewhere herein, thereby rendering the host cell selectable, then targeting the vector's integration by including on this a likewise non-functional copy of same host gene of a size that allows homologous recombination between the two different copies of the non-functional host genes in the genome of the host cell and on the integration vector, tailored so that such a recombination will restore a functional copy of the gene, thus leaving the host cell selectable. Or the vector may simply comprise a functional copy of the conditionally essential gene, to select for integration anywhere in the genome.

A preferred embodiment of the invention relates to the cell of the invention, wherein a first amplification unit integrates into the host cell chromosome by homologous recombination with the partially deleted conditionally essential gene and renders the gene functional.

A preferred embodiment of the invention relates to the cell of the invention, wherein the gene of interest encodes a polypeptide of interest, preferably the polypeptide is an enzyme such as a protease; a cellulase; a lipase; a xylanase; a phospholipase; or preferably an amylase.

Another preferred embodiment of the invention relates to the cell of the invention, wherein the polypeptide is a hormone, a pro-hormone, a pre-pro-hormone, a small peptide, a receptor, or a neuropeptide.

Still another preferred embodiment of the invention relates to the cell of the invention, wherein the gene of interest encodes an enzyme, preferably an amylolytic enzyme, a lipolytic enzyme, a proteolytic enzyme, a cellulolytic enzyme, an oxidoreductase or

10442.000-DK

a plant cell-wall degrading enzyme, and more preferably an enzyme with an activity selected from the group consisting of aminopeptidase, amylase, amyloglucosidase, carbohydrase, carboxypeptidase, catalase, cellulase, chitinase, cutinase, cyclodextrin glycosyltransferase, deoxyribonuclease, esterase, galactosidase, beta-galactosidase, glucoamylase, glucose
5 oxidase, glucosidase, haloperoxidase, hemicellulase, invertase, isomerase, laccase, ligase, lipase, lyase, mannosidase, oxidase, pectinase, peroxidase, phytase, phenoloxidase, polyphenoloxidase, protease, ribonuclease, transferase, transglutaminase, or xylanase.

In a preferred embodiment, the invention relates to a cell, wherein the gene of interest encodes an antimicrobial peptide, preferably an anti-fungal peptide or an anti-
10 bacterial peptide, or a peptide with biological activity in the human body, preferably a pharmaceutically active peptide, more preferably insulin/pro-insulin/pre-pro-insulin or variants thereof, growth hormone or variants thereof, or blood clotting factor VII or VIII or variants thereof.

Conditionally essential genes are well-characterized in the literature, for instance
15 genes that are required for a cell to synthesize one or more amino acids, where a non-functional gene encoding a polypeptide required for synthesis of an amino acid renders the cell auxotrophic for that amino acid, and the cell can only grow if the amino acid is supplied to the growth medium. Restoration of the functionality of such a gene, or complementation by providing an exogenous functional copy of such a gene, allows the cell to synthesise the
20 amino acid on its own, and it becomes selectable against a background of auxotrophic cells.

Consequently, a preferred embodiment of the invention relates to a cell of the first aspect, wherein the conditionally essential chromosomal gene(s) of the host cell encodes one or more polypeptide(s) involved in amino acid synthesis, and the non-functionality of the endogenous versions of the gene(s) renders the cell auxotrophic for one or more amino
25 acid(s), and wherein restoration of the functionality of the gene(s) renders the cell prototrophic for the amino acid(s).

Bacillus subtilis metE encodes a S-adenosyl-methionine synthetase, the *metE*/*MetE* sequences are available from EMBL:BS52812 (accession no. U52812) (Yocum, R.R.; Perkins, J.B.; Howitt, C.L.; Pero, J.; 1996. Cloning and characterization of the *metE* gene
30 encoding S-adenosylmethionine synthetase from *Bacillus subtilis*. J. Bacteriol. 178(15):4604).

The *leuB* gene encodes 3-isopropylmalate dehydrogenase, which catalyses the conversion of 3-carboxy-2-hydroxy-4-methylpentanoate to 3-carboxy-4-methyl-2-oxopentanoate. A *leuB*-deficient strain will be a leucine auxotroph.

35 The *lysA* gene encoding diaminopimelate decarboxylase, which catalyses the conversion of Meso-2,6-diaminoheptanedioate to L-lysine. A *lysA*-deficient strain will be a lysine auxotroph.

A preferred embodiment relates to a cell of the invention, wherein the conditionally essential gene encodes an enzyme from the biosynthetic pathway of an amino acid; preferably the conditionally essential gene encodes one or more polypeptide(s) involved in lysine, leucine or methionine synthesis, preferably the conditionally essential gene is
5 homologous to the *lysA*, *leuB*, *metC*, or the *metE* gene from *Bacillus subtilis*, and more preferably the conditionally essential gene is the *lysA*, *leuB*, *metC*, or *metE* gene from *Bacillus licheniformis*; more preferably the conditionally essential gene is at least 75% identical, preferably 85% identical, more preferably 95% and most preferably at least 97% identical to the *lysA* sequence of *Bacillus licheniformis* shown in SEQ ID NO:48 of WO
10 02/00907 A1, the *leuB* sequence of *Bacillus licheniformis*, the *metC* sequence of *Bacillus licheniformis* shown in SEQ ID NO:42 of WO 02/00907 A1, or the *metE* sequence of *Bacillus subtilis* shown in positions 987 to 2199 of SEQ ID NO:16.

The *hemA* gene encodes glutamyl-tRNA reductase, which catalyses the synthesis of 5-amino leuvulinic acid. A *hemA*-deficient strain will have to be supplemented with 5-amino
15 leuvulinic acid or haemin.

In another embodiment, the conditionally essential gene encodes a glutamyl-tRNA reductase, preferably the conditionally essential gene is homologous to the *hemA* gene from *Bacillus subtilis*, and more preferably the conditionally essential gene is the *hemA* gene from *Bacillus licheniformis*; preferably the conditionally essential gene is at least 75% identical,
20 preferably 85% identical, more preferably 95% and most preferably at least 97% identical to the *hemA* sequence of *Bacillus licheniformis*.

The conditionally essential gene(s) may encode polypeptides involved in the utilization of specific carbon sources such as xylose, glucanate, glycerol, or arabinose, in which case the host cell is unable to grow in a minimal medium supplemented with only that
25 specific carbon source when the gene(s) are non-functional.

A preferred embodiment of the invention relates to a cell of the invention, wherein the at least one conditionally essential chromosomal gene(s) is one or more genes that are required for the host cell to grow on minimal medium supplemented with only one specific main carbon-source.

30 A preferred embodiment relates to a cell of the invention, wherein the at least one conditionally essential gene encodes an enzyme required for xylose utilization, preferably the conditionally essential gene is homologous to the *xylA* gene from *Bacillus subtilis*, and more preferably the conditionally essential gene is homologous to a gene of the xylose isomerase operon of *Bacillus licheniformis*, most preferably to the *xylA* gene of *Bacillus licheniformis*;
35 preferably the conditionally essential gene encodes a xylose isomerase and is at least 75% identical, preferably 85% identical, more preferably 95% and most preferably at least 97% identical to the *xylA* gene of *Bacillus licheniformis*.

Another preferred embodiment relates to a cell of the invention, wherein the at least one conditionally essential gene encodes an enzyme required for gluconate utilization, preferably the conditionally essential gene encodes a gluconate kinase (EC 2.7.1.12) or a gluconate permease, more preferably the gene is homologous to the *gntK* gene or the *gntP* gene from *Bacillus subtilis*, and most preferably the gene is the *gntK* or *gntP* gene from *Bacillus licheniformis*; preferably the conditionally essential gene encodes a gluconate kinase (EC 2.7.1.12) or a gluconate permease or both and is at least 75% identical, preferably 85% identical, more preferably 95% and most preferably at least 97% identical to any of the *gntK* and *gntP* sequences of *Bacillus licheniformis*.

Still another preferred embodiment relates to a cell of the invention, wherein the conditionally essential gene encodes an enzyme required for glycerol utilization, preferably the conditionally essential gene encodes a glycerol uptake facilitator (permease), a glycerol kinase, or a glycerol dehydrogenase, more preferably the conditionally essential gene is homologous to the *glpP*, *glpF*, *glpK*, or the *glpD* gene from *Bacillus subtilis*, and most preferably the conditionally essential gene comprises one or more of the *glpP*, *glpF*, *glpK*, and *glpD* genes from *Bacillus licheniformis* shown in SEQ ID NO:26 of published PCT application WO 02/00907 A1 (Novozymes A/S) which is incorporated herein by reference in its totality; preferably the conditionally essential gene encodes a glycerol uptake facilitator (permease), a glycerol kinase, or a glycerol dehydrogenase, and is at least 75% identical, preferably 85% identical, more preferably 95% and most preferably at least 97% identical to any of the *glpP*, *glpF*, *glpK*, and *glpD* sequences of *Bacillus licheniformis* shown in SEQ ID NO:26 of WO 02/00907 A1.

One more preferred embodiment relates to a cell of the invention, wherein the conditionally essential gene encodes an enzyme required for arabinose utilization, preferably an arabinose isomerase, more preferably the gene is homologous to the *araA* gene from *Bacillus subtilis*, and most preferably the gene is the *araA* gene from *Bacillus licheniformis* shown in SEQ ID NO:38 of WO 02/00907 A1; preferably the conditionally essential gene encodes an arabinose isomerase, and is at least 75% identical, preferably 85% identical, more preferably 95% and most preferably at least 97% identical to the *araA* sequence of *Bacillus licheniformis* shown in SEQ ID NO:38 of WO 02/00907 A1.

The amplification unit in the cell of the invention may also include an antibiotic marker gene. However, as it is preferred not to have marker genes in the chromosome, an alternative way of removing the marker gene must be employed. Specific restriction enzymes denoted resolvases excise portions of DNA if each portion is flanked on both sides by certain recognition sequences known as resolvase sites or *res*-sites; these resolvase enzymes are well-known in the art, see e.g. WO 96/23073 (Novo Nordisk A/S) which is included herein by reference.

A preferred embodiment relates to a cell of the invention, wherein the amplification unit further comprises an antibiotic selection marker, preferably the selection marker is flanked by resolvase sites or *res*-sites.

Subsequent to the action of the resolvase enzyme, the antibiotic restriction marker
5 flanked by *res*-sites will have been excised from the chromosome of the cell, leaving only one copy of the *res*-site behind as testimony to the procedure.

Accordingly, a preferred embodiment relates to a cell of the invention, wherein the amplification unit further comprises a resolvase site or *res*-site.

As the present invention relies on a reduced transcription of the conditionally
10 essential gene comprised in the amplification unit as compared to its wild-type transcription level, it may be an advantage to include one or more transcription terminators upstream of the gene in different reading frames, in order to avoid any unintentional read-through transcription from a gene further upstream in the chromosome from where the unit was integrated.

15 A preferred embodiment relates to a cell of the invention, wherein the conditionally essential gene comprised in the amplification unit has at least one transcription terminator located upstream of the gene.

Another way of reducing transcription of the conditionally essential gene is to express it from a heterologous or completely artificial promoter, which has a reduced activity
20 as compared to the wild-type or endogenous promoter normally transcribing said gene. Preferably, the conditionally essential gene is transcribed from a heterologous promoter having an activity level, when compared with the endogenous promoter of the conditionally essential gene, which is reduced with a factor of 2, preferably 5, more preferably 10, even more preferably 50, and most preferably with a factor of 100.

25 Still another strategy could be to have a promoterless conditionally essential gene in the amplification unit, and then simply rely on what read-through transcription there might from any other gene(s) located upstream of the conditionally essential gene, before or after integration of the unit into the chromosome of the cell of the invention. Preferably, the conditionally essential gene is promoterless; and more preferably the gene of interest is
30 located upstream of the conditionally essential gene in the amplification unit, so that the two genes are co-directionally transcribed, whereby the conditionally essential gene is expressed by read-through transcription from the gene of interest.

A second aspect of the invention relates to a method for producing a protein encoded by a gene of interest, comprising

- 35 a) culturing a bacterial host cell comprising at least two duplicated copies of an amplification unit in its genome, the amplification unit comprising:
- i) at least one copy of the gene of interest, and

- ii) an expressible conditionally essential gene, wherein the conditionally essential gene is either promoterless or transcribed from a heterologous promoter having an activity substantially lower than the endogenous promoter of said conditionally essential gene,

5 wherein the conditionally essential gene if not functional would render the cell auxotrophic for at least one specific substance or unable to utilize one or more specific sole carbon source; and

- b) recovering the protein.

10 As already mentioned, any cell of the invention is envisioned to be suitable in the methods of the second aspect, in particular the preferred embodiments outlined in the above.

A final aspect of the invention relates to methods for producing a bacterial cell comprising two or more amplified chromosomal copies of a gene of interest, the method comprising:

- 15 a) providing a bacterial cell comprising at least one copy of an amplification unit, the unit comprising:

- i) at least one copy of the gene of interest, and
ii) an expressible functional copy of a conditionally essential gene, which is either promoterless or transcribed from a heterologous promoter having an activity substantially lower than the endogenous promoter of said conditionally essential gene,

20 wherein the conditionally essential gene if not functional would render the cell auxotrophic for at least one specific substance or unable to utilize one or more specific sole carbon source;

- 25 c) cultivating the cell under conditions suitable for growth in a medium deficient of said at least one specific substance and/or with said one or more specific sole carbon source, thereby providing a growth advantage to a cell in which the amplification unit has been duplicated in the chromosome; and

- 30 c) selecting a cell wherein the amplification unit has been duplicated in the chromosome, whereby two or more amplified chromosomal copies of the gene of interest were produced.

Again, as already mentioned, the methods of the final aspect of the invention are envisioned as being suitable for producing any cell of the invention, in particular the preferred embodiments of said cell that are outlined in the above.

35 EXAMPLES

Strains and Donor Organisms

Bacillus subtilis PL1801. This strain is the *B. subtilis* DN1885 with disrupted *apr* and *npr* genes (Diderichsen, B., Wedsted, U., Hedegaard, L., Jensen, B. R., Sjøholm, C. (1990)

10442.000-DK

Cloning of *aldB*, which encodes alpha-acetolactate decarboxylase, an exoenzyme from *Bacillus brevis*. J. Bacteriol., 172, 4315-4321).

B. subtilis CLO46. This strain is a *B. subtilis* PL1801 where the *metE* gene is deleted and replaced with the kanamycine (*kan*) resistance gene from pUB110 by use of the plasmid pCLO43.

B. subtilis CLO49. This strain is the CLO46 strain where the kanamycine resistance gene is deleted.

Competent cells were prepared and transformed as described by Yasbin, R.E., Wilson, G.A. and Young, F.E. (1975) Transformation and transfection in lysogenic strains of *Bacillus subtilis*: evidence for selective induction of prophage in competent cells. J. Bacteriol, 121:296-304.

Plasmids

pCLO43:

This plasmid is a pBR322 derivative (Watson, N., 1988 Gene 70(2):399-403) essentially containing elements making the plasmid propagatable in *E. coli*, a ampicillin resistance gene, a gene conferring resistance to kanamycine, two flanking fragments from *B. subtilis metE* inserted upstream and downstream of the kanamycine resistance gene, two direct repeats that signify the *res* site from pAMBeta1 (Janniere, L., 1996, Nucleic Acids Res. 24(17):3431-3436. This plasmid is used for deleting the *metE* gene in the *B. subtilis* strain PL1801.

Table 1. Plasmid pCLO43, 7311 bp

Position (bp)	Size (bp)	Element (bp)	Origin
1-973	973	Upstream <i>metE</i> seq.	<i>B. subtilis</i>
974-1010	37	Linker	Synthetic
10111-1184	174	<i>res</i> site from pAMBeta1	<i>E. faecalis</i>
1185-1190	6	Linker	Synthetic
1191-2159	969	pUB110 (Kan gene)	<i>S. aureus</i>
2160-2162	3	Linker	Synthetic
2163-2336	174	<i>res</i> site from pAMB β 1	<i>E. faecalis</i>
2337-2357	21	Linker	Synthetic
2358-3870	1513	Downstream <i>metE</i> seq.	<i>B. subtilis</i>
3871-7311	3441	pBR322	<i>E. coli</i>

pCLO1154

This plasmid is a pBR322 derivative (Watson, N., 1988 *Gene* 70(2):399-403) containing elements making the plasmid propagatable in *E. coli*. The plasmid codes for the ampicillin resistance gene, the kanamycine resistance gene, the chloramphenicol resistance gene and the *lacZ* gene from *E. coli*. The *gfp* gene from *A. victoria* and the *metE* gene from *B. subtilis* are transcriptionally fused in the plasmid controlled by a promoter that can be exchanged with other promoters. This plasmid is used for integration and amplification studies in the *amyE* locus of CLO49. The primers for *metE* fragment PCR amplifications on chromosomal DNA isolated from PL1801 are as follows:

P52 (SEQ ID NO: 1): a ataataaagatctggaggagaaacaatgacaacc

P53 (SEQ ID NO: 2): a aataataagatctaaattatactagctgtgtc

Table 2. Plasmid pCLO1154, 13135 bp.

Position (bp)	Size (bp)	Element (bp)	Origin
1-539	539	Upstream <i>amyE</i>	<i>B. subtilis</i>
540-2853	2314	<i>metE</i> gene	<i>B. subtilis</i>
2854-2891	38	Linker	Synthetic
2892-3605	714	<i>gfp</i> gene	<i>A. victoria</i>
3606-3739	134	Promoter - <i>air</i>	<i>B. subtilis</i>
3740-3785	46	Linker	Synthetic
3786-4821	1036	pC194 (<i>cat</i> gene)	<i>S. aureus</i>
4822-5008	187	part of <i>tetC</i> gene	<i>E. coli</i>
5009-5106	98	Promoter	Synthetic
5107-5111	6	Linker	Synthetic
5112-8224	3113	<i>spoVG-lacZ</i> fusion	<i>B. subtilis</i> & <i>E. coli</i>
8226-8314	89	part of <i>tetC</i> gene	<i>E. coli</i>
8315-9657	1343	Downstream <i>amyE</i>	<i>B. subtilis</i>
9658-9845	188	Linker	Synthetic
9846-11117	1272	pUB110 (<i>neo</i> gene)	<i>S. aureus</i>
11118-11184	67	Linker	Synthetic
11185-11277	93	Tn5 fragment	<i>E. coli</i>

11278-11281	4	Linker	Synthetic
11282-13119	1838	pBR322 (<i>bla</i> gene)	<i>E. coli</i>
13120-13129	10	Linker	Synthetic

Propagation of PL1801 strain for LacZ activity determination

The *B. subtilis* strain PL1801 was propagated in liquid medium TY. After 10 generations of incubation at 37°C and 300 rpm, the cells were harvested, and cells were disrupted by sonic or lysozyme treatment.

General molecular biology methods

Unless otherwise mentioned the DNA manipulations and transformations were performed using standard methods of molecular biology (Sambrook et al. (1989) Molecular cloning: A laboratory manual, Cold Spring Harbor lab., Cold Spring Harbor, NY; Ausubel, F. M. et al. (eds.) "Current protocols in Molecular Biology". John Wiley and Sons, 1995; Harwood, C. R., and Cutting, S. M. (eds.) "Molecular Biological Methods for Bacillus". John Wiley and Sons, 1990).

Enzymes for DNA manipulations were used according to the specifications of the suppliers (e.g. restriction endonucleases, ligases etc. are obtainable from New England Biolabs, Inc.).

Media

TY: (as described in Ausubel, F. M. et al. (eds.) "Current protocols in Molecular Biology". John Wiley and Sons, 1995). LB agar (as described in Ausubel, F. M. et al. (eds.) "Current protocols in Molecular Biology". John Wiley and Sons, 1995).

Minimal TSS agar: As described in Fouet A. and Sonenshein, A. L. (1990) A Target for Carbon Source-Dependant Negative Regulation of the *citB* Promoter of *Bacillus subtilis*. J. Bacteriol., 172, 835-844. For plates, 2% agar was added and for methionine auxotrophy determination the plates were supplemented with 50 microg/ml methionine.

Assay for beta-galactosidase activity

Beta-galactosidase activity was determined by a method using ortho-nitrophenyl-beta-D-galactopyranoside as enzymatic substrate. Under a specified set of conditions (temp., pH, reaction time, buffer conditions) a given amount of beta-galactosidase will degrade a certain amount of substrate and a yellow colour will be produced. The colour intensity is measured at 420 nm. The measured absorbance is directly proportional to the activity of the beta-galactosidase in question under a given set of conditions.

Deletion of *metE* in *B. subtilis*

A plasmid was constructed for the purpose of deleting the *metE* gene in *B. subtilis*. Two flanking sequences upstream and downstream of the *galE* gene were amplified by PCR and fused by PCR on each side of a kanamycine (Kana) marker. This fragment was ligated in plasmid pBR322.

Upstream *metE* fragment:

P42 (SEQ ID NO: 3): atttataggatcccgctgattcatttcttctgcgaac

P43 (SEQ ID NO: 4): gaattccatcgacactggacgacatttcaggctcgattctcggaatcc

Downstream *metE* fragment:

P44 (SEQ ID NO: 5): ccgaggccttcaggcccgcaacaatatggtgaagccgcaaacagg

P45 (SEQ ID NO: 6): ataataatggtaccatattgatgtgacactgaagtgc

The resulting plasmid pCLO43 (SEQ ID NO: 7) was linearised and transferred to *B. subtilis* PL1801 and plated on LBPG media with 10 µg/ml kanamycine, which left the Kan marker in place of the *metE* gene.

A *metE* deletion strain designated CLO46 was tested on minimal media without methionine. The original *B. subtilis* PL1801 (*metE*⁺) strain showed fine growth on these plates while the *metE*⁻ strain CLO46 showed no growth even after several days of incubation. On control minimal plates supplemented with 50 µg/ml methionine, both strains grew. The reported auxotrophic phenotype on a *metE*⁻ strain is therefore confirmed.

The Kan marker located in the *metE* locus of CLO46 was flanked by resolvase recognition sites (*res*), which allow a specific excision reaction in the presence of a resolvase. In order to remove the Kan marker from the chromosome, CLO46 was transformed with pWT, which is a temperature sensitive plasmid that comprises a gene coding for resolvase and an erythromycin (Erm) resistance marker. Transformants were selected on plates with 5 µg/ml Erm. They were tested for loss of the Kan marker and further re-streaked twice on plates with no antibiotics at 50°C to cure the strains of the pWT plasmid. Selected clones were screened for loss of Erm resistance and Kan resistance and were designated CLO49 (PL1801, *metE*⁻; no antibiotic markers).

Amplification plasmids

An amplification plasmid was made having a transcriptional unit consisting of the *gfp* gene and the *metE* gene with a cloning site in front of the two genes, wherein a promoter could be cloned (pCLO1154, SEQ ID NO: 8). The *lacZ* reporter gene was also present on the

plasmid expressed from a promoter separate from the promoter in front of the *metE* gene. Flanking these two transcriptional units was fragments from the *amyE* locus in *B. subtilis*.

Promoters with varying promoter activity were cloned in front of the *gfp-metE* transcriptional unit in the *EcoRI* and *HindIII* sites. The promoter activities spanned from 30 to 519 arbitrary units. See table 3.

Promoter	Activity / Units	Sequence
Pr30	30	(SEQ ID NO: 9)
Pr43	43	(SEQ ID NO: 10)
Pr119	119	(SEQ ID NO: 11)
Pr164	164	(SEQ ID NO: 12)
Pr342	342	(SEQ ID NO: 13)
Pr409	409	(SEQ ID NO: 14)
Pr519	519	(SEQ ID NO: 15)

Table 3: The table shows the promoters used in the amplification experiment and the sequence is given.

Amplification experiments

The resulting amplification plasmids were introduced by transformation into CLO49 (*metE*⁻) and plated on solid LB media supplemented with 6 microg/ml chloramphenicol. Transformants were screened for resistance to kanamycine.

Transformants being sensitive to kanamycine would have integrated part of the amplification plasmid at the *amyE* locus including the *lacZ* reporter gene and the *gfp-metE* operon. Those transformants would have only one copy of the genes present and they cannot be amplified.

Transformants being resistant to kanamycine would have the whole amplification plasmid integrated at the *amyE* locus and amplification would be possible.

Both types of transformants were plated on solid minimal TSS media without methionine. Several colonies were obtained from the transformants having the whole plasmid integrated at the *amyE* locus, whereas the transformants that had only part of the plasmid integrated showed no growth on minimal medium. This indicated that even with the strongest promoter, one copy of the *metE* gene did not express sufficient MetE protein to complement the methionine auxotrophy of the strain. However, amplification of the *metE* gene did result in growth of the strain.

Colonies were picked from the amplification step along with colonies that had only one copy of the *metE* gene integrated in the chromosome. They were all grown in liquid LB

10442.000-DK

and harvested in the exponential growth phase followed by measurement of β -galactosidase activity. The following table gives the results from the evaluation of the amplification outcomes.

A few clones show irregular enzyme activities, which can be explained by up-
5 mutations in the promoters.

Promoter Strength	Strain	Units	Copies
30	1 gene copy	105	1,0
	Amplification	1361	12,4
	Amplification	218	2,0
43	1 gene copy	101	0,9
	Amplification	1467	13,4
	Amplification	1460	13,3
119	1 gene copy	113	1,0
	Amplification	1055	9,6
	Amplification	1075	9,8
164	1 gene copy	102	0,9
	Amplification	881	8,0
	Amplification	855	7,8
342	1 gene copy	134	1,2
	Amplification	606	5,5
409	1 gene copy	105	1,0
	Amplification	533	4,9
	Amplification	493	4,5
519	1 gene copy	105	1,0
	Amplification	544	5,0
	Amplification	114	1,0

Table 4: The table shows the results from the amplification trials and the β -galactosidase activity measured in all strains after growth in LB lipid media. The enzyme activities have been converted to the gene copy number of the reporter gene based on the enzyme
10 activities.

The results summarized herein show that it is indeed possible to increase the copy number of a chromosomally integrated expression cassette holding a weakly expressed *metE* gene by growing the strain on minimal medium without methionine. The amplification potential >10 copies (up to 25 copies have been observed), as judged from the enzyme
15 activities is very similar to what can be achieved by the traditional kanamycine antibiotic selection/amplification.

CLAIMS

1. A bacterial host cell comprising at least two copies of an amplification unit in its genome, said amplification unit comprising:
 - i) at least one copy of a gene of interest, and
 - 5 ii) an expressible conditionally essential gene, wherein the conditionally essential gene is either promoterless or transcribed from a heterologous promoter having an activity substantially lower than the endogenous promoter of said conditionally essential gene, andwherein the conditionally essential gene if not functional would render the cell auxotrophic for
10 at least one specific substance or unable to utilize one or more specific sole carbon source.
2. The cell of claim 1, wherein the bacterial cell is a prokaryotic cell.
3. The cell of claim 2, wherein the bacterial prokaryotic cell is a Gram-positive cell.
- 15 4. The cell of claim 3, wherein the bacterial Gram positive cell is a species of the genus *Bacillus*, preferably selected from the group consisting of *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus brevis*, *Bacillus circulans*, *Bacillus coagulans*, *Bacillus lautus*, *Bacillus lentus*, *Bacillus licheniformis*, *Bacillus megaterium*, *Bacillus stearothermophilus*,
20 *Bacillus subtilis*, and *Bacillus thuringiensis*.
5. The cell of any of claims 1-4, wherein the gene of interest encodes an enzyme, preferably an amylolytic enzyme, a lipolytic enzyme, a proteolytic enzyme, a cellulytic enzyme, an oxidoreductase or a plant cell-wall degrading enzyme, and more preferably an
25 enzyme with an activity selected from the group consisting of aminopeptidase, amylase, amyloglucosidase, carbohydrase, carboxypeptidase, catalase, cellulase, chitinase, cutinase, cyclodextrin glycosyltransferase, deoxyribonuclease, esterase, galactosidase, beta-galactosidase, glucoamylase, glucose oxidase, glucosidase, haloperoxidase, hemicellulase, invertase, isomerase, laccase, ligase, lipase, lyase, mannosidase, oxidase, pectinase,
30 peroxidase, phytase, phenoloxidase, polyphenoloxidase, protease, ribonuclease, transferase, transglutaminase, or xylanase.
6. The cell of any of claims 1-4, wherein the gene of interest encodes an antimicrobial peptide, preferably an anti-fungal peptide or an anti-bacterial peptide.
- 35 7. The cell of any of claims 1-4, wherein the gene of interest encodes a peptide with biological activity in the human body, preferably a pharmaceutically active peptide, more

preferably Insulin/pro-insulin/pre-pro-Insulin or variants thereof, growth hormone or variants thereof, or blood clotting factor VII or VIII or variants thereof.

8. The cell of any of claims 1-7, wherein the conditionally essential gene encodes an enzyme from the biosynthetic pathway of an amino acid.

9. The cell of claim 8, wherein the conditionally essential gene encodes one or more polypeptide(s) involved in lysine, leucine or methionine synthesis, preferably the conditionally essential gene is homologous to the *lysA*, *leuB*, *metC*, or the *metE* gene from *Bacillus subtilis*, and more preferably the conditionally essential gene is the *lysA*, *leuB*, *metC*, or *metE* gene from *Bacillus licheniformis*.

10. The cell of claim 8, wherein the conditionally essential gene is at least 75% identical, preferably 85% identical, more preferably 95% and most preferably at least 97% identical to the *lysA* sequence of *Bacillus licheniformis* shown in SEQ ID NO:48 of WO 02/00907 A1, the *leuB* sequence of *Bacillus licheniformis*, the *metC* sequence of *Bacillus licheniformis* shown in SEQ ID NO:42 of WO 02/00907 A1, or the *metE* sequence of *Bacillus subtilis* shown in positions 997 to 2199 of SEQ ID NO:16.

11. The cell of any of claims 1-7, wherein the conditionally essential gene encodes a glutamyl-tRNA reductase, preferably the conditionally essential gene is homologous to the *hemA* gene from *Bacillus subtilis*, and more preferably the conditionally essential gene is the *hemA* gene from *Bacillus licheniformis*.

12. The cell of any of claims 1-7, wherein the conditionally essential gene is at least 75% identical, preferably 85% identical, more preferably 95% and most preferably at least 97% identical to the *hemA* sequence of *Bacillus licheniformis*.

13. The cell of any of claims 1-7, wherein the conditionally essential gene encodes an enzyme required for xylose utilization, preferably the conditionally essential gene is homologous to the *xylA* gene from *Bacillus subtilis*, and more preferably the conditionally essential gene is homologous to a gene of the xylose isomerase operon of *Bacillus licheniformis*, most preferably to the *xylA* gene of *Bacillus licheniformis*.

14. The cell of any of claims 1-7, wherein the conditionally essential gene encodes a xylose isomerase and is at least 75% identical, preferably 85% identical, more preferably 95% and most preferably at least 97% identical to the *xylA* gene of *Bacillus licheniformis*.

15. The cell of any of claims 1-7, wherein the conditionally essential gene encodes an enzyme required for gluconate utilization, preferably the conditionally essential gene encodes a gluconate kinase (EC 2.7.1.12) or a gluconate permease, more preferably the gene is homologous to the *gntK* gene or the *gntP* gene from *Bacillus subtilis*, and most preferably the gene is the *gntK* or *gntP* gene from *Bacillus licheniformis*.

16. The cell of any of claims 1-7, wherein the conditionally essential gene encodes a gluconate kinase (EC 2.7.1.12) or a gluconate permease or both and is at least 75% identical, preferably 85% identical, more preferably 95% and most preferably at least 97% identical to any of the *gntK* and *gntP* sequences of *Bacillus licheniformis*.

17. The cell of any of claims 1-7, wherein the conditionally essential gene encodes an enzyme required for glycerol utilization, preferably the conditionally essential gene encodes a glycerol uptake facilitator (permease), a glycerol kinase, or a glycerol dehydrogenase, more preferably the conditionally essential gene is homologous to the *glpP*, *glpF*, *glpK*, or the *glpD* gene from *Bacillus subtilis*, and most preferably the conditionally essential gene comprises one or more of the *glpP*, *glpF*, *glpK*, and *glpD* genes from *Bacillus licheniformis* shown in SEQ ID NO:26 of WO 02/00907 A1.

18. The cell of any of claims 1-7, wherein the conditionally essential gene encodes a glycerol uptake facilitator (permease), a glycerol kinase, or a glycerol dehydrogenase, and is at least 75% identical, preferably 85% identical, more preferably 95% and most preferably at least 97% identical to any of the *glpP*, *glpF*, *glpK*, and *glpD* sequences of *Bacillus licheniformis* shown in SEQ ID NO:26 of WO 02/00907 A1.

19. The cell of any of claims 1-7, wherein the conditionally essential gene encodes an enzyme required for arabinose utilization, preferably an arabinose isomerase, more preferably the gene is homologous to the *araA* gene from *Bacillus subtilis*, and most preferably the gene is the *araA* gene from *Bacillus licheniformis* shown in SEQ ID NO:38 of WO 02/00907 A1.

20. The cell of any of claims 1-7, wherein the conditionally essential gene encodes an arabinose isomerase, and is at least 75% identical, preferably 85% identical, more preferably 95% and most preferably at least 97% identical to the *araA* sequence of *Bacillus licheniformis* shown in SEQ ID NO:38 of WO 02/00907 A1.

21. The cell of any of claims 1-20, wherein the amplification unit further comprises an antibiotic selection marker, preferably the selection marker is flanked by resolvase sites or res-sites.
- 5 22. The cell of any of claims 1-20, wherein the amplification unit further comprises a resolvase site or res-site.
23. The cell of any of claims 1-22, wherein the conditionally essential gene comprised in the amplification unit has at least one transcription terminator located upstream of the gene.
- 10 24. The cell of any of claims 1-23, wherein the conditionally essential gene is transcribed from a heterologous promoter having an activity level, when compared with the endogenous promoter of the conditionally essential gene, which is reduced with a factor of 2, preferably 5, more preferably 10, even more preferably 50, and most preferably with a factor
- 15 of 100.
25. The cell of any of claims 1-23, wherein the conditionally essential gene is promoterless.
- 20 26. The cell of claim 25, wherein the gene of interest is located upstream of the conditionally essential gene in the amplification unit, and wherein the two genes are co-directionally transcribed.
27. The cell of claim 26, wherein the conditionally essential gene is expressed by read-
25 through transcription from the gene of interest.
28. A method for producing a protein encoded by a gene of interest, comprising
a) culturing a bacterial host cell comprising at least two duplicated copies of an amplification unit in its genome, the amplification unit comprising:
30 i) at least one copy of the gene of interest, and
ii) an expressible conditionally essential gene, wherein the conditionally essential gene is either promoterless or transcribed from a heterologous promoter having an activity substantially lower than the endogenous promoter of said conditionally essential gene,
35 wherein the conditionally essential gene if not functional would render the cell auxotrophic for at least one specific substance or unable to utilize one or more specific sole carbon source; and
b) recovering the protein.

29. A method for producing a bacterial cell comprising two or more amplified chromosomal copies of a gene of interest, the method comprising:

a) providing a bacterial cell comprising at least one copy of an amplification unit, the unit

5 comprising:

i) at least one copy of the gene of interest, and

ii) an expressible functional copy of a conditionally essential gene, which is either promoterless or transcribed from a heterologous promoter having an activity substantially lower than the endogenous promoter of said conditionally essential

10 gene,

wherein the conditionally essential gene if not functional would render the cell auxotrophic for at least one specific substance or unable to utilize one or more specific sole carbon source;

c) cultivating the cell under conditions suitable for growth in a medium deficient of said at least one specific substance and/or with said one or more specific sole carbon source, thereby providing a growth advantage to a cell in which the amplification unit has been duplicated in the chromosome; and

15

c) selecting a cell wherein the amplification unit has been duplicated in the chromosome, whereby two or more amplified chromosomal copies of the gene of interest were

20

produced.

TITLE: Method for stable gene-amplification in a bacterial host cell

ABSTRACT

A bacterial host cell comprising at least two copies of an amplification unit in its
5 genome, said amplification unit comprising: i) at least one copy of a gene of interest, and ii)
an expressible conditionally essential gene, wherein the conditionally essential gene is either
promoterless or transcribed from a heterologous promoter having an activity substantially
lower than the endogenous promoter of said conditionally essential gene, and wherein the
10 conditionally essential gene if not functional would render the cell auxotrophic for at least one
specific substance or unable to utilize one or more specific sole carbon source; methods for
producing a protein using the cell of the invention, and methods for constructing the cell of
the invention.

01-SQ Listing-31 Oct 2003.ST25.txt
SEQUENCE LISTING

<110> Novozymes A/S

<120> metE gene-amplification

<130> 10442.000-DK

<160> 17

<170> PatentIn version 3.2

<210> 1

<211> 35

<212> DNA

<213> artificial sequence

<220>

<223> Primer P52

<400> 1

aataataag atctggagga gaaacaatga caacc

35

<210> 2

<211> 33

<212> DNA

<213> artificial sequence

<220>

<223> Primer P53

<400> 2

aaataataag atctaaatta tactagctgt gtc

33

<210> 3

<211> 39

<212> DNA

<213> artificial sequence

<220>

<223> Primer P42

<400> 3

attttatagg atcccgtga ttcattttct tctgcgaac

39

<210> 4

<211> 48

<212> DNA

<213> artificial sequence

<220>

<223> Primer P43

<400> 4

gaattccatc gcactggacg acattttcag gtcgattctc ggaaatcc

48

<210> 5

<211> 50

<212> DNA

<213> artificial sequence

<220>

<223> Primer P44

01-SQ Listing-31 Oct 2003.ST25.txt

<400> 5
cccaggccct ttcaggcccg caaacaatat ggttgaagct gcaaaacagg 50

<210> 6
<211> 39
<212> DNA
<213> artificial sequence

<220>
<223> Primer P45

<400> 6
ataataatgg taccatattg atgtgacact tgaagttgc 39

<210> 7
<211> 7311
<212> DNA
<213> artificial sequence

<220>
<223> Plasmid pCLO43

<400> 7
cttgaggggc caagcgatgt gccagagcta aaagaagcag tgaaaaacgc agtgaaaaac 60
ggagtgtcttgc tcttttctgc agcgggaaat gaagggtgacg gcgacgaacg cacagaagag 120
ctttcctacc cgcagctta taatgaagtg attgcagttg gatctgtttc tgtagcgcga 180
gaattatcag aattttctaa cgcgaataaa gagattgacc ttgtggcacc aggagaaaac 240
atcttatcca cctttcccaa caagaagtac ggtaagctga ccggcacttc aatggctgcc 300
cctcatgtca gcggtgcgct tgctttaatc aaaagctatg aagaagaatc atttcaaaga 360
aagctttctg aatctgaggt ttctgcacag ctaatccgca ggacacttcc tcttgatatt 420
gcaaaaacgc tggcaggcaa tggattcctg tatttaacag ctctgatga gctcgcagaa 480
aaagcagagc aatcacattt gttgacctta taagattatt ttctttatat aatatacacc 540
acatcatgta aataaaaatt tcaaattcta tgttgacaat gaatttgaat tactgttaag 600
attaccaaca aatgattcaa cttttcaaaa aattaataac attttctctt atcgagagtt 660
gggcgaggga ttggcctttt gaccccaaca gcaaccgacc gtaataccat tgtgaaatgg 720
ggcgcaactgc ttttcgcgcc gagactgatg tctcataagg cacggtgcta attccatcag 780
atttgtgtctg agagatgaga gaggcagtgt ttacgtaga aaagcctctt tctctcatgg 840
gaaagaggct tttgtttgtg agaaaacctc ttagcagcct gtatccgcgg gtgaaagaga 900
gtgttttaca tataaaggag gagaacaat gacaaccatc aaaacatcga atttaggatt 960
tccgagaatc gacctgaaaa tgcgtccag tgcgatggaa ttctgatcaa atggttcagt 1020
gagagcgaag cgaacacttg attttttaat tttctatctt ttataggtca ttagagtata 1080
cttatttgc ctataaacta ttagcagca taatagattt attgaatagg tcatttaagt 1140
tgagcatatt agaggaggaa aatcttgag aaatatttga agaaccgaa cgcgtgagta 1200
gttcaacaaa cgggccagtt tgttgaagat tagatgctat aattgttatt aaaaggattg 1260
aaggatgctt aggaagacga gttattaata gctgaataag aacggtgctc tccaaatatt 1320

01-SQ Listing-31 Oct 2003.ST25.txt

cttatttaga aaagcaaattc taaaattatc tgaaggga atgagaatag tgaatggacc	1380
aataataatg actagagaag aaagaatgaa gattgttcat gaaattaagg aacgaataat	1440
ggataaatat ggggatgatg ttaaggctat tgggtttat ggctctcttg gtcgtcagac	1500
tgatgggccc tattcggata ttgagatgat gtgtgtcatg tcaacagagg aagcagagtt	1560
cagccatgaa tggacaaccg gtgagtggaa ggtggagtg aattttgata gcgaagagat	1620
tctactagat tatgcatctc aggtggaatc agattggccg ctacacatg gtcaattttt	1680
ctctattttg ccgatttatg attcaggtgg atacttagag aaagtgtatc aaactgctaa	1740
atcggtagaa gcccaaactg tccacgatgc gatttgtgcc ctatcgtag aagagctgtt	1800
tgaatatgca ggcaaatggc gtaatatctg tgtgcaagga ccgacaacat ttctaccatc	1860
cttgactgta caggtagcaa tggcaggtgc catgttgatt ggtctgcac atcgcatctg	1920
ttatagacg agcgtctcg tcttaactga agcagttaag caatcagatc ttccttcagg	1980
ttatgacat ctgtgccagt tctgaatgtc tgggtcaact tccgactctg agaaacttct	2040
ggaatcgcta gagaatttct ggaatgggat tcaggagtgg acagaacgac acggatatat	2100
agtggatgtg tcaaaacgca taccattttg aacgatgacc tctaataatt gttaatcatg	2160
ttggagctca gtgagagcga agcgaacact tgatttttta attttctatc ttttataggt	2220
cattagagta tacttatttg tctataaac tatttagcag cataatagat ttattgaata	2280
ggtcatttaa gttgagcata ttagaggagg aaaatcttg agaaatattt gaagaacccg	2340
aggcctttca ggcccgcaaa caatatggtt gaagccgcaa aacaggcaag agcacagcag	2400
acacagctag tataatttga aaaaaccatc tgcatttggc agatggtttt tttctataat	2460
acagccacaa tgggtttctt atttagcaaa tcccccaat actttgttta ttttgactt	2520
ttttaaagaat gttctttgca ttttttctcg ctatactaat aacactctat tgacaggagg	2580
gattgggatg aatcatgaaa cgttcttaaa acgggctgtc actctcgcat gtgaaggagt	2640
gaatgcagga atcggcgggc cttttggagc cgttatcgtg aaagacggag ccattattgc	2700
agagggacag aacaacgtca caacaagcaa tgatccgact gccacgcgg aagtcacagc	2760
tattcggaaa gcctgtaagg tgctaggagc ctaccagctt gatgactgca ttttgatatac	2820
gagctgtgaa ccatgcccaa tgtgcttggg cgccatctac tgggcccggc ctaaagccgt	2880
tttctatgca gctgagcaca cagacgtgc cgaagccggg ttgatgatt cattcattta	2940
taaagaaatt gataaacctg ctgaagaaag aacgatcccc ttttatcaag tgacactaac	3000
agagcattta tccccgttc aagcatggcg gaacttcgcc aataagaaag aatattaaaa	3060
ggatcaggca tgcgcggcct ggtccttgtt atttttcaa gtagccgcta tgcctgtgc	3120
aaatacaaaa cagcatatac gcgcaattca gcacggcaga caccgtgcc gccacccgct	3180
tcactgtcaa cttttggttt aaaggcatgc ttcaaacgct tctctgaagt tttatcataa	3240
atctgtgcc gccccgatg tccgacacca aaaaacatc tgagaatcct caggatgccg	3300
gtcattattt taattctagt ttacatcaa ctttctctt ggttgcctt gagtaaggac	3360

01-SQ Listing-31 Oct 2003.ST25.txt

```

agaattcatg agcggcggtg acaagctcct gtgccttttc ccgatctaaa tctttcgtgt 3420
tcacaacaag tgtgacaccg attttaaac cgccgtcgtc ctcatccttc atgaggctga 3480
cctgcccctc aatctccgaa tcaatttcga tattctgctc ttgggtacg tgttcgagcg 3540
cgccgccgaa gcatgcagca tacctgcgcg caaagagctg tcccgattt gtgccggttt 3600
gtccttcttt ttggcattt ggcatgacaa tatcaaaatc aagaacaccg tcatctgatg 3660
taatatgtcc tgcctcgtcc cctcgcgcgg ttacttttgc tgtaaatagt gccatatttc 3720
ccaacctcct tatttgatc tagttgttat atttcccttt ctgatctttt taaacatgct 3780
atgtttgccg agaataggaa aagtgaggtt ttccagatac aatagaatcg aatgacaaaa 3840
aagagrtggt gaacaaaatg gaaaataaat ttgatcatat gcggtgtgaa ataccgcaca 3900
gatgcgtaag gagaaaatac cgcatacaggc gctcttccgc ttcttcgctc actgactcgc 3960
tgcgctcggc cgttcggctg cggcgagcgg tatcagctca ctcaaaggcg gtaatacggc 4020
tatccacaga atcaggggat aacgcaggaa agaacatgtg agcaaaaggc cagcaaaagg 4080
ccaggaaccg taaaagggtc gcgttgctgg cgtttttcca taggtccgc cccctgacg 4140
agcatcacia aaatcgacgc tcaagtcaga ggtggcgaaa cccgacagga ctataaagat 4200
accaggcggt tccccctgga agctccctcg tgcgctctcc tgttccgacc ctgccgctta 4260
ccggatacct gtccgccttt ctcccttcgg gaagcgtggc gctttctcat agctcacgct 4320
gtaggratct cagttcgggt taggtcgttc gctccaagct gggctgtgtg cacgaacccc 4380
ccgttcagcc cgaccgctgc gccttatccg gtaactatcg tcttgagtcc aaccgggtaa 4440
gacacgactt atcgccactg gcagcagcca ctggtaacag gattagcaga gcgaggatg 4500
taggcgggtg tacagagttc ttgaagtggc ggcctaacta cggctacact agaaggacag 4560
tatttgggtat ctgcgctctg ctgaagccag ttacctcgg aaaaagagtt ggtagctctt 4620
gatccggcaa acaaaccacc gctggtagcg gtgggttttt tgtttgcaag cagcagatta 4680
cgcgagaaaa aaaaggatct caagaagatc ctttgatctt ttctacgggg tctgacgctc 4740
agtggaaacg aaactcacgt taagggattt tggtcatgag attatcaaaa aggatcttca 4800
cctagatcct tttaaattaa aaatgaagtt ttaaatcaat ctaaagtata tatgagtaaa 4860
cttggctcga cagttaccaa tgcttaatca gtgaggcacc tatctcagcg atctgtctat 4920
ttcgttcatc catagttgcc tgactccccg tcgtgtagat aactacgata cgggagggct 4980
taccatctgg cccagtgct gcaatgatac cgcgagaccc acgctcaccc gctccagatt 5040
tatcagcaat aaaccagcca gccggaaggc cggagcgag aagtggctct gcaactttat 5100
ccgctccat ccagtctatt aattgttgcc gggagagctag agtaagtagt tcgccagtta 5160
atagtttgcg caacgttggt gccattgctg caggcatcgt ggtgtcacgc tcgtcgtttg 5220
gtatcgcttc attcagctcc ggttcccaac gatcaaggcg agttacatga tccccatgt 5280
tgtgcaaaaa agcggtagc tccttcgggc ctccgatcgt tgtcagaagt aagttggcgg 5340
cagtgttatc actcatgggt atggcagcac tgcataatc tcttactgtc atgccatccg 5400

```

01-SQ Listing-31 Oct 2003.ST25.txt

```

taagatgctt ttctgtgact ggtgagtact caaccaagtc attctgagaa tagtgatatgc 5460
ggcgaccgag ttgtctttgc ccggcgtaaa cacgggataa taccgcgcca catagcagaa 5520
ctttaaaagt gctcatcatt ggaaaacggt ctctggggcg aaaactctca aggatcttac 5580
cgctgttgag atccagttcg atgtaaccca ctctgacacc caactgatct tcagcatctt 5640
ttactttcac cagcgtttct gggtgagcaa aaacaggaag gcaaatgcc gcaaaaaagg 5700
gaataagggc gacacggaaa tgrtgaatac tcatactctt cctttttcaa tattattgaa 5760
gcatttatca gggttattgt ctcatgagcg gatacatatt tgaatgtatt tagaaaaata 5820
aacaatatag gggtccgcgc acatttcccc gaaaagtgcc acctgacgtc taagaaacca 5880
ttattatcat gacattaacc tataaaaaata ggcgatcac gaggcccttt cgtcttcaag 5940
aattctcatg ttgacagct tatcatcgat aagctttaat gcggtagttt atcacagtta 6000
aattgctaac gcagtcaggc accgtgtatg aaatctaaca atgcgctcat cgtcatcttc 6060
ggcaccgtca ccctggatgc tgtaggcata ggcttggtta tgccgggtact gccgggcctc 6120
ttgcgggata tcgtccattc cgacagcatc gccagtcact atggcggtgt gctagcgcta 6180
tatgcgttga tgcaatttct atgcgcaccc gttctcggag cactgtccga ccgctttggc 6240
cgccgccag tctgtctgc ttctgtactt ggagccacta tcgactacgc gatcatggcg 6300
accacaccgc tcctgtggat cctctacgcc ggacgcattc tggccggcat caccggcgcc 6360
acaggtgagg ttgctggcgc ctatatcgcc gacatcaccg atggggaaga tcgggctcgc 6420
cacttcgggc tcatgagcgc ttgtttcggc gtgggtatgg tggcaggccc cgtggccggg 6480
ggactgttgg gcgccatctc ctgcatgca ccattcttg cggcggcggt gctcaacggc 6540
ctcaacctac tactgggctg ttctctaata gaggagtcgc ataagggaga gcgtcgaccg 6600
atgcccttga gagccttcaa ccagtcagc tccttcgggt gggcgcgggg catgactatc 6660
gtcgccgcac ttatgactgt ctctcttata atgcaactcg taggacagggt gccggcagcg 6720
ctctgggtca ttttcggcga ggaccgcttt cgtggagcg cgacgatgat cggcctgtcg 6780
cttgcggtat tcggaatctt gcacgcccc gctcaagcct tcgtcaetgg tcccgccacc 6840
aaacgtttcg gcgagaagca ggccattatc gccggcatgg cggccgacgc gctgggctac 6900
gtcttgctgg cgttcgcgac gcgaggctgg atggccttcc ccattatgat tcttctcgct 6960
tccggcggca tcgggatgcc cgcgttgag gccatgctgt ccaggcagggt agatgacgac 7020
catcagggac agcttcaagg atcgctcgc gctcttacca gcctaacttc gatcactgga 7080
ccgctgatcg tcacggcgat ttatgccgcc tcggcgagca catggaacgg gttggcatgg 7140
attgtaggcg ccgccctata ccttgtctgc ctcccgcgt tgcgtcgcgg tgcattggagc 7200
cgggccacct cgacctgaat ggaagccggc ggcacctgc taacggattc accactccaa 7260
gaattggagc caatcaattc ttgcggagaa ctgtgaatgc gcaaaccaac c 7311

```

<210> 8
<211> 13129

01-SQ Listing-31 Oct 2003.ST25.txt

<212> DNA
 <213> artificial sequence

<220>
 <223> Plasmid pCLO1154

<220>
 <221> misc_feature
 <222> (5067)..(5067)
 <223> n is a, c, g, or t

```

<400> 8
aacaaaattc tccagtcctc acatcggttt gaaaggagga agcgggaagaa tgaagtaaga      60
gggatttttg actccgaagt aagtccttcaa aaaatcaaat aaggagtgtc aagaatgttt      120
gcaaaacgat tcaaaacctc ttactgccg ttattcgctg gatttttatt gctgtttcat      180
ttggttctgg caggaccggc ggctgcgagt gctgaaacgg cgaacaaatc gaatgagctt      240
acagcaccgt cgatcaaaag cgggaaccatt ctcatgcat ggaattggc gttcaatacg      300
ttaaaccaca atatgaagga tttcatgat gcaggatata cagccattca gacatctccg      360
attaaccaag taaaggaagg gaatcaagga gataaaagca tgtcgaactg gtactggctg      420
tatcagccga catcgtatca aattggcaac cgttacttag gtactgaaca agaatttaaa      480
gaaatgtgtg cagccgctga agaatatggc ataaaggtca ttgttgacgc gcggccgcgg      540
atctaaatta tactagctgt gtctgtctgt ctctgcctg ttttgcggct tcaaccatat      600
ttttcaatgc tgcaaccgtt tcttccctgt gtctgtttt caatccgcag tctggattta      660
cccagaagcg gtcagtcgga cagacggcaa gcgcataac gataatatg tacatttctt      720
cagttgacgg cacacgaggg ctgtgaatgt catatacacc aaggccaagc cctttcaaat      780
acgggtggtt ttttaagtaa tctaaaaatc ctccgtggct tctgctatgt tcgattgtaa      840
tcacatcggc atcaagatca ttgattgtat caacgatatc tcgaagttg ctgtagcaca      900
tatgtgtatg aatttgtgtc tcgtttttca cggagaagt ggtaaatctg aaagcttctg      960
ccgcccaagt caaatactca tcccaatcgc gggttttcaa tggaaggcct tcacgcagcg      1020
ctggttcacg gacttgaatg atttgaatgc ctgctcttc aagcgttta acttctttgc      1080
gaagggcaag cccgatttgg aaggcgattt ctttccctga gatgtcgtt cgaggggaaag      1140
accagtttaa gattgtaacc gggcccgtca gcattccttt cacatgcttg gaagtcaatg      1200
actgtgcgta gactgtgtct ttactgtca tcggttcaat aaattcaaca tctccgtaaa      1260
tgactggcgg gcggacacag cgtgagccgt atgattgaac ccaggcatat ttagtgaagg      1320
cgaaaccggc cagcttttca ccgaagtatt cgaccatgtc tgtccgttca aattcgccgt      1380
gaacaaggac atcaagctcc aattcttctt gaatatcaat ccatcttttt gtttccgcac      1440
tgataaagtt ttgatactgt tcacggacc actcagcttt ccgccatttt tggcgtgccc      1500
tccgcacttc agcagactgc gggaaactgc cgatcgttgt cgtcggcaaa agcgggaaggc      1560
cgagagattc attttgtagg gctaaacgtt ctccaacgg aatcgggcgc ttgaagtctt      1620
tatcagttaa ttgctcaagc tctttctttt gttcagaatt ggcgcctgtt gcaaactgtt      1680

```

01-SQ Listing-31 Oct 2003.ST25.txt

taagcgctg gatatcagcc ttagcctgct gaatctcttc gctgatcgcc gcttttcctg	1740
atactaagcc ttctttcaaa gctgtcagct cggccagctt ttcttttgcg taggataatc	1800
cgttcaatag gtctttttcc aatgctcat caggggtgtt cgctactgga acatcgagca	1860
ggctgctgga aggctgaatc cacagttcat caacttttgc aatgctgaga acatcaagaa	1920
cggcatcgag actctcttca aggtccgctt tccaaatggt gcgtccgtcg ataacgccgg	1980
ctgccagcac ttatctgtc gggaagccat gtgttttaag ctgttccagg ttctgcctt	2040
tgtctgaac gaaatcaagg ccaattccct gaaccgggta agagatcagc tcttcataag	2100
catcaacaga atcaaaatac gtctgcaaaa gcacattcaa ggatgaaagc tcacttgtaa	2160
tgctttcaaa taattctttt gcgcgcgcta catcttcat agaggcggta acgagcgccg	2220
gctcatcgat ttgaacccat ttacgcctt ctctttcaag ctctttcaaa agctgtacat	2280
ataatggcac aaggcgtrtt tggatcgctt ttgcttcaga cggttcatag cctttagcaa	2340
gcgtaacgaa cgtataaggg cggacaatca caggctttgt ttccacaccg tattcctgtt	2400
tgatccggcg ataattctcg agttgtttgt ttctgtcag acggaactca atgctctcgt	2460
catattccgg aacgatgtaa tggtaatttg tattaaacca ttttgtcatt tctactagata	2520
cagcgtcttt gattccgcgg gcgatagcga agtatgtatc ggtagcgtca gtcaaatgtc	2580
tgaaccgttt cgggatccag ttgaagctga ctgctgtgtc gagtacatgg tcatactgtg	2640
tgaatcaga aacaggcaca acatcaatct gctggccaat ttgtgttttt actgcgata	2700
aaaatagttc gtcgatttgc ttcaaaaacg tatctttatc agtactgcct ttccaatacg	2760
cttcaagtgc ttttttccat tcccggttca ggtcgattct cggaaatcct aaattcgatg	2820
ttttgatggt tgtcattgtt tctcctccag atccgtcgac ctgcataaac tgcattcctt	2880
aacttgtttt atttgtatag ttcatccatg ccatgtgtaa tcccagcagc tgttacaac	2940
tcaagaagga tcatgtgatc tctcttttcg ttgggatctt tggaaagggc agattgcgtg	3000
gacaggtaat ggttgtcttg taaaaggaca gggccatcgc caattggagt attttgttga	3060
taatggctcg ctaattgaac gcttccatct ttaatgttgt gtctaatttt gaagttaact	3120
ttgatgccat tctttggttt gtctgccatg atgtatacat tatgtgagtt ataattgtat	3180
tccattttgt gtccaagaat gtctccatct tctttaaaat caataccttt taactcgatt	3240
ctattaacaa gggtatcacc ttcaaacttg acctcagcac gtgtcttcta gtccccgtca	3300
tctttgtaaa atatagttct ttctgttaca taaccttcgg gcatggcact cttgaaaaag	3360
tcatgctgtt tcatatgatc tgggtatcta gaaaagcatt gaacaccata agagagagta	3420
gtgacaagcg ttggccatgg aacaggtagc ttcccagtag tgcaaataaa ttttaagggt	3480
agttttccgt atgttgcatc accttcaccc tctccactaa cagagaattt ttgcccatta	3540
acatcgccat ctaattcaac aagaattggg acaactccag tgaaaagtcc ttctccttta	3600
ctcataaagc tccccctcta gcttttatcc aatatcattt acatatcata ctaaaattaa	3660
aggctaaagg gaaacgatgt ctaacgaaaa aaaggccaaa tcatgtttgg cctttggcgg	3720

01-SQ Listing-31 Oct 2003.ST25.txt

```

ttatttcgat gattgtcccc aattctggcc ctttaaggcca attctcatgt ttgacagctt 3780
atcatcggca atagttaccc ttattatcaa gataagaaag aaaaggattt ttcgctacgc 3840
tcaaatcett taaaaaaaca caaaagacca ctttttttaa tgtggctttt attcttcaac 3900
taaagcacc attagttcaa caaacgaaaa ttggataaag tgggatattt ttaaaatata 3960
tatttatggt acagtaatat tgacttttaa aaaaggattg attctaataga agaaagcaga 4020
caagtaagcc tcctaaattc accttagata aaaatttagg aggcataatca aatgaacttt 4080
aataaaattg atttagacaa ttggaagaga aaagagatat ttaatcatta ttgaaaccaa 4140
caaacgactt ttagtataac cacagaaatt gatattagt tttataaccg aaacataaaa 4200
caagaaggat ataaatttta ccttgcatth atttcttag tgacaagggg gataaactca 4260
aatacagctt ttagaactgg ttacaatagc gacggagagt taggttattg ggataagtta 4320
gagccacttt atacaatttt tgatgggtgt tctaaaacat tctctgggtat ttggactcct 4380
gtaaagaatg acttcaaaga gttttatgat ttataccttt ctgatgtaga gaaatataat 4440
ggttcgggga aattgtttcc caaaacacct atacctgaaa atgctttttc tctttctatt 4500
attccatgga cttcatttac tgggtttaac ttaaataatca ataataatag taattacctt 4560
ctaccatta ttacagcagg aaaattcatt aataaaggta attcaatata ttaccgcta 4620
tctttacagg tacatcatcc tgtttgtgat ggttatcatg caggattggt tatgaactct 4680
attcaggaat tgtcagatag gcctaattgac tggcttttat aatatgagat aatgccgact 4740
gtacttttta cagtcgggtt tctaattgtca ctaacctgcc ccgttaggtg aagaagggtt 4800
ttatattaca gctccagatc ctctacgccg gacgcacgt ggccggcatc accggcgcca 4860
cagggtcggt tgcctggccc tatatcgctg acatcaccga tggggaagat cgggctcgcc 4920
acttcgggct catgagcgct tgtttcggcg tgggtatggt ggcaggcccc gtggccgggg 4980
gactgttggg cgccatctcc ttgcatgccc agaaatttat ccttaagctg gattcaggaa 5040
gaggggcgtt tgacaggaag ggggagnagg catataatga gatgagact gttaactggg 5100
caggatggat cccagcttg ttgatacact aatgctttta tatagggaaa aggtggtgaa 5160
ctactgtgga agttactgac gtaagattac gggtcgaccg ggaaaaccct ggcgttacc 5220
aacttaatcg ccttgagca catccccctt tcgccagctg gcgtaatagc gaagaggccc 5280
gcaccgatcg ccttcccaa cagttgcga gccgaatgg cgaatggcg tttgcctggt 5340
ttccggcacc agaagcgggt ccggaaagct ggctggagt cgcatttctt gaggccgata 5400
ctgtcgtcgt cccctcaaac tggcagatgc acggttacga tgcgccatc tacaccaacg 5460
taacctatcc cattaagggtc aatccgccgt ttgttccac ggagaatccg acgggttggt 5520
actcgtcac atttaatggt gatgaaagct ggctacagga aggccagacg cgaattattt 5580
ttgatggcgt taactcggcg ttcatctgt ggtgcaacgg gcgctgggtc ggttacggcc 5640
aggacagtcg ttgcccgtc gaatttgacc tgagcgcat tttacgcgcc ggagaaaacc 5700
gcctcgcggt gatgggtgct cgctggagt acggcagtta tctggaagat caggatatgt 5760

```


01-SQ Listing-31 Oct 2003.ST25.txt

```

ggcgatgag cggcattttc cgtgacgtct cgttgctgca taaaccgact acacaaatca 5820
gcgatttcca tgrtgccact cgctttaatg atgatttcag ccgcgctgta ctggaggctg 5880
aagttcagat gtgcggcgag ttgctgact acctacgggt aacagtttct ttatggcagg 5940
gtgaaacgca ggtcgccagc ggcaccgcgc ctttcggcgg tgaaattatc gatgagcgtg 6000
gtggttatgc cgatcgctc acactacgtc tgaacgtcga aaaccgaaa ctgtggagcg 6060
ccgaaatccc gaatctctat cgtgcggttg ttgaactgca caccgccgac ggcacgctga 6120
ttgaagcaga agcctgcgat gtcggtttcc gcgagggtgc gattgaaaat ggtctgctgc 6180
tgctgaacgg caagccgttg ctgattcgag gcgttaaccg tcacgagcat catcctctgc 6240
atggtcaggt catggatgag cagacgatgg tgcaggatat cctgctgatg aagcagaaca 6300
actttaacgc cgtgcgctgt tcgcattatc cgaaccatcc gctgtggtac acgctgtgcg 6360
accgctacgg cctgtatgtg gtggatgaag ccaatatga aaccacggc atggtgccaa 6420
tgaatcgctc gaccgatgat ccgcgctggc taccggcgat gacggaacgc gtaacgcgaa 6480
tggtgcagcg cgatcgtaat cacccgagtg tgatcatctg gtcgctgggg aatgaatcag 6540
gccacggcgc taatcacgac gcgctgtatc gctggatcaa atctgtcgat ccttcccgcc 6600
cgggtgcagta tgaaggcggc ggagccgaca ccacggccac cgatattatt tgcccgatgt 6660
acgcgcgcgt ggatgaagac cagcccttcc cggctgtgcc gaaatgggtcc atcaaaaaat 6720
ggctttcgt acctggagag acgcgcccgc tgatcctttg cgaatacgcc cagcgatgg 6780
gtaacagtct tggcggtttc gctaaatact ggcaggcgtt tcgtcagtat ccccgtttac 6840
agggcggtt cgtctgggac tgggtggatc agtcgctgat taaatatgat gaaaacggca 6900
acccgtggtc ggcttacggc ggtgattttg gcgatacgcc gaacgatcg cagttctgta 6960
tgaacggtct ggtctttgcc gaccgcacgc cgcattccagc gctgacggaa gcaaaacacc 7020
agcagcagtt ttccagttc cgtttatccg ggcaaaccat cgaagtgacc agcgaatacc 7080
tgrttcgtca tagcgataac gagctcctgc actggatggt ggcgctggat ggtaagccgc 7140
tggcaagcgg tgaagtgcct ctggatgtcg ctccacaagg taaacagttg attgaactgc 7200
ctgaactacc gcagccggag agcgccgggc aactctggct cacagtacgc gtagtgcaac 7260
tgaacgcgac cgcattggtc gaagccgggc acatcagcgc ctggcagcag tggcgtctgg 7320
cggaaaacct cagtgtgacg ctccccgcgc cgtcccacgc catcccgcac ctgaccacca 7380
gcgaaatgga tttttgcac gagctgggta ataagcgttg gcaatttaac cgccagtcag 7440
gctttctttc acagatgtgg attggcgata aaaaacaact gctgacgccg ctgcgcgac 7500
agttcacccg tgcaccgctg gataacgaca ttggcgtaag tgaagcgacc cgcattgacc 7560
ctaacgcctg ggtcgaacgc tgggaaggcg cgggccatta ccaggccgaa gcagcgttgt 7620
tgcagtgcac ggcagataca cttgctgatg cgggtgctgat tacgaccgct cagcgtggc 7680
agcatcaggg gaaaacctta ttatcagcc ggaaaacctt cggattgat ggtagtgtc 7740
aaatggcgat taccgttgat gttgaagtgg cgagcgatac accgcattccg gcgcggattg 7800

```

01-SQ Listing-31 Oct 2003.ST25.txt

gcctgaactg ccagctggcg caggtagcag agcgggtaaa ctggctcgga ttagggccgc	7860
aagaaaaacta tcccgaccgc cttactgccc cctgttttga ccgctgggat ctgccattgt	7920
cagacatgta taccctgtac gtcttcccca gcgaaaacgg tctgcgctgc gggacgcgcg	7980
aattgaatta tggccacac cagtggcgcg gcgacttcca gttcaacatc agccgctaca	8040
gtcaacagca actgatggaa accagccatc gccatctgct gcacgcggaa gaaggcacat	8100
ggctgaatat cgacggtttc catatgggga ttgggtggcg cgactcctgg agcccgctcag	8160
tatcggcgga attacagctg agcggccggtc gctaccatta ccagttgggtc tgggtgtcaaa	8220
aataagcatg caccattcct tgcggcgggc gtgctcaacg gcctcaacct actactgggc	8280
tgccttctaa tgcaggagtc gcataagggg gagcgtcgac atggatgagc gatgatgata	8340
tccgttttagg ctgggcggtg atagcttctc gttcaggcag tacgcctctt ttcttttcca	8400
gacctgaggg aggcggaaat ggtgtgaggt tcccggggaa aagccaaata ggcgatcgcg	8460
ggagtgcctt atttgaagat caggctatca ctgcggtcaa tagatttcac aatgtgatgg	8520
ctggacagcc tgaggaactc tcgaacccga atggaaacaa ccagatattt atgaatcagc	8580
gcggctcaca tggcgttgtg ctggcaaatg caggttcatc ctctgtctct atcaatacgg	8640
caacaaaatt gcctgatggc aggtatgaca ataaagctgg agcgggttca ttcaagtga	8700
acgatggtaa actgacaggc acgatcaatg ccaggtctgt agctgtgctt tatcctgatg	8760
atattgcaaa agcgcctcat gttttccttg agaattacaa aacagggtgt acacattctt	8820
tcaatgatca actgacgatt accttgctg cagatgcgaa tacaacaaaa gccgtttatc	8880
aaatcaataa tggaccagac gacaggcgtt taaggatgga gatcaattca caatcgga	8940
aggagatcca atttggcaaa acatacacca tcatgttaaa aggaacgaac agtgatgggtg	9000
taacgaggac cgagaaatac agttttgtta aaagagatcc agcgtcggcc aaaaccatcg	9060
gctatcaaaa tccgaatcat tggagccagg taaatgctta tatctataaa catgatggga	9120
gccgagtaat tgaattgacc ggatcctggc ctggaaaacc aatgactaaa aatgcagacg	9180
gaatttacac gctgacgctg cctgcggaca cggatacaac caacgcaaaa gtgattttta	9240
ataatggcag cgcccaagtg cccggtcaga atcagcctgg ctttgattac gtgctaaatg	9300
gtttatataa tgactcgggc ttaagcgggt ctcttcccca ttgagggcaa ggctagatgg	9360
gacttaccga aagaaacat caatgatggt ttcttttttg ttcataaatc agacaaaact	9420
tttctcttgc aaaagtctgt gaagtgttgc acaatataaa tgtgaaatac ttcacaaaca	9480
aaaagacatc aaagagaaac ataccctgca aggatgctga tattgtctgc atttgcgccg	9540
gagcaaacca aaaacctggt gagacacgcc ttgaattagt agaaaagaac ttgaagattt	9600
tcaaaggcat cgttagtgaa gtcatggcg gaggatttga cggcattttc ttagtcggta	9660
acaatcctcg ttaaaggaca aggacctgag cggagtgta tcgtacagta gacggagtat	9720
actagtatag tctatagtcc gtggaattat tatatttate tccgacgata ttctcatcag	9780
tgaatccag ctggagtctt ttagcaaat tttttattag ctgaacttag tattagtggg	9840

01-SQ Listing-31 Oct 2003.ST25.txt

```

gccgctgata attactaata ctaggagaag ttaataaata cgtaaccaac atgattaaca 9900
attattagag gtcacgttc aaaatggtat gcgttttgac acatccacta tatatccgtg 9960
tcgttctgtc cactcctgaa tcccattcca gaaattctct agcgattcca gaagtttctc 10020
agagtcggaa agttgaccag acattacgaa ctggcacaga tggtcataac ctgaagggaag 10080
atctgattgc ttaactgctt cagttaagac cgaagcgctc gtcgtataac agatgcgatg 10140
atgcagacca atcaacatgg cacctgccat tgcctcctgt acagtcaagg atggtagaaa 10200
tggtgtcggc ccttgcacac gaattattacg ccatttgcct gcatattcaa acagctcttc 10260
tacgataagg gcacaaatcg catcgtggaa cgtttgggct tctaccgatt tagcagtttg 10320
atacactttc tctaagtatc cacctgaatc ataaatcggc aaaatagaga aaaattgacc 10380
atgtgtaagc ggccaatctg attccacctg agatgcataa tctagtagaa tctcttcgct 10440
atcaaaattc acttccacct tccactcacc ggttgtccat tcatggctga actctgcttc 10500
ctctgttgac atgacacaca tcatttcaat atccgaatag ggcccatcag tctgacgacc 10560
aagagagcca taaacaccaa tagccttaac atcatcccca tatttatcca atattcgttc 10620
cttaatttca tgaacaatct tcattcttcc ttctctagtc attattattg gtccattcac 10680
tattctcatt ccttttctag ataattttag atttgccttt ctaaataaga atatttggag 10740
agcaccgctc ttattcagct attaataact cgtcttccca agcatcatgg tctcactttt 10800
ccactttttg tcttgtccac taaaaccctt gatcttccat ctgaataaat gctactatta 10860
ggacacataa tattaanaaga aacccccatc tatttagtta tttgtttagt cacttataac 10920
tttaacagat ggggtttttc tgtgcaacca attttaaggg ttttcaatac tttaaaacac 10980
atacatacca acacttcaac gcacctttca gcaactaaaa taaaaatgac gttatttcta 11040
tatgtatcaa gataagaaaag aacaagttca aaaccatcaa aaaaagacac cttttcaggt 11100
gcttttttta ttttataaac tcattccctg atctcccatc actcctcaa tccaaagcta 11160
tttagaaaaga ttactatata ctcaaacagg cggtaaccgg cctcttcata gggaatgcgc 11220
gcgaccttca gcatcgccgg catgtcccc tggcggacgg gaagtatcca gctcgaggtc 11280
gggcccgcgtt gctggcgctt tccataggg tccgcccccc tgacgagcat cacaaaaatc 11340
gacgctcaag tcagaggtgg cgaaaccca caggactata aagataccag gcgtttcccc 11400
ctggaagctc cctcgtgcgc tctcctgttc cgacctgccc gcttaccgga tacctgtccg 11460
cctttctccc ttcgggaagc gtggcgcttt ctcatagctc acgctgtagg tatctcagtt 11520
cgggtgtaggt cgttcgctcc aagctgggct gtgtgcacga accccccgtt cagcccgacc 11580
gctgcgcctt atccggtaac tatcgtcttg agtccaaccc ggtaagacac gacttatcgc 11640
cactggcagc agccactggt aacaggatta gcagagcgag gtatgtaggc ggtgctacag 11700
agttcttgaa gtgggtggct aactacggct acactagaag gacagtattt ggtatctgcg 11760
ctctgctgaa gccagttacc ttcggaaaaa gagtggtag ctcttgatcc ggcaaaaaa 11820
ccaccgctgg tagcgggtgt tttttgttt gcaagcagca gattacgcgc agaaaaaaag 11880

```

01-SQ Listing-31 Oct 2003.ST25.txt

```

gatctcaaga agatcctttg atcttttcta cggggtctga cgctcagtgg aacgaaaact 11940
cacgttaagg gatttttggtc atgagattat caaaaaggat cttcacctag atccttttaa 12000
attaaaaatg aagtttttaa tcaatctaaa gtatatatga gtaaacctgg tctgacagtt 12060
accaatgctt aatcagtgag gcacctatct cagcgatctg tctatttcgt tcatccatag 12120
ttgectgact ccccgtcgtg tagataacta cgatacggga gggcttacca tctggcccca 12180
gtgctgcaat gataccgcga gaccacgct caccggctcc agatttatca gcaataaacc 12240
agccagccgg aagggccgag cgcagaagtg gtcctgcaac tttatccgcc tccatccagt 12300
ctattaattg ttgccgggaa gctagagtaa gtagttcgcc agttaatagt ttgcgcaacg 12360
ttggtgcat tgcctgaggc atcgtggtgt cagctcgtc gtttggtatg gcttcattca 12420
gctccgggtc ccaacgatca aggcgagtta catgatccc catgttggtc aaaaaagcgg 12480
ttagctcctt cggctcctcg atcgttgta gaagtaagtt ggccgcagtg ttatcactca 12540
tggttatggc agcactgcat aattctctta ctgctatgcc atccgtaaga tgcttttctg 12600
tgactggtga gtactcaacc aagtcattct gagaatagtg tatgcggcga ccgagttgct 12660
cttgcccgcc gtcaacacgg gataataccg cgccacatag cagaacttta aaagtgtca 12720
tcattgaaa acgttcttcg gggcgaaaac tctcaaggat cttaccgctg ttgagatcca 12780
gttcgatgta atccactcgt gcacccaact gatcttcagc atcttttact ttcaccagcg 12840
tttctgggtg agcaaaaaca ggaaggcaaa atgccgcaaa aaaggggaata agggcgacac 12900
ggaaatgttg aatactcata ctcttccttt ttcaatatta ttgaagcatt tatcaggggt 12960
attgtctcat gagcggatac atatttgaat gtatttagaa aaataaacia ataggggttc 13020
cgcgcacatt tccccgaaa gtgccacctg acgtctaaga aaccattatt atcatgacat 13080
taacctataa aaataggcgt atcacgaggc ctttcgtct tcaagaatt 13129

```

<210> 9
 <211> 87
 <212> DNA
 <213> artificial sequence

<220>
 <223> Promoter PR30

```

<400> 9
gaattcatgc atcgcggagg tgagatttga cactagtagg ctacgggact ataatgcggg 60
aagtactggt aactgcagga taagctt 87

```

<210> 10
 <211> 86
 <212> DNA
 <213> artificial sequence

<220>
 <223> Promoter PR43

```

<400> 10
gaattcatgc attcgaattt ggaaatcgac aggagcgggc gggtagggta taataratgt 60

```

01-SQ Listing-31 Oct 2003-STZ5.txt

agtactgtta actgcaggat aagctt

86

<210> 11
<211> 87
<212> DNA
<213> artificial sequence

<220>
<223> Promoter PR119

<400> 11
gaattcatgc atcgagcgga agtttgttga cacagctcca ggatacaaat ataatgggtc 60
gagtactgtt aactgcagga taagctt 87

<210> 12
<211> 86
<212> DNA
<213> artificial sequence

<220>
<223> Promoter PR164

<400> 12
gaattcatgc atggacagtt cgtctttgac aaatctaaga aaggggaacta taatgtgggc 60
agtactgtta actgcaggat aagctt 86

<210> 13
<211> 87
<212> DNA
<213> artificial sequence

<220>
<223> Promoter PR342

<400> 13
gaattcatgc atgcggatgg aaggggttga caccggcgcc ggggtccaggt ataattcttga 60
cagtactgtt aactgcagga taagctt 87

<210> 14
<211> 87
<212> DNA
<213> artificial sequence

<220>
<223> Promoter PR409

<400> 14
gaattcatgc atagaggagt ttattcttga caaatgcgag gcagaatggt ataatacgtg 60
gagtactgtt aactgcagga taagctt 87

<210> 15
<211> 87
<212> DNA
<213> artificial sequence

<220>
<223> Promoter PR519

01-SQ Listing-31 Oct 2003.ST25.TXT

<400> 15
gaattcatgc atagtaaagt ttattcttga caagaattgg cgcgggtgat ataataaata 60
cagtactgtt aactgcagga taagctt 87

<210> 16
<211> 2591
<212> DNA
<213> *Bacillus subtilis*

<220>
<221> CDS
<222> (997)..(2199)
<223> MetE coding sequence

<400> 16
ggatccgctt tgaatgcgg agcagaaaga atggtgaacg gctgctcaac tgttttctta 60
tcatttcctt ccggacggat aaacagctgc cgcgcaaata aattgtgcca tgcgaactca 120
tttacgacag tgatcggcag cctgtatttc tcgtctgctc cggcaaattcc ttcgaaaaca 180
aacagttcat ctgcctcctt taaatagctg acaactttcg tgtacagccg ctcaaacgct 240
tcttctgaaa tcggctgatt caccggggccc caatcgatct tatttttctg gctttcttcc 300
tccacgatga atttatcttt aggtgagcgt cctgtgtaag cgctgttgt cgcgcaaca 360
gcacctgtgg atgttaaaat gccttcgttt cgggagagga ctttttctgt tagctgtgct 420
gctgataaat tatgacgcac atttgacat gtttaataagg cttgtgaatc agcgggtcaa 480
tcaactgagt tcatatgaaa ccttccctta tcgttttttg tgttttgcta attgtgaatt 540
agtataacat atattttcaa atagctctata ctatttattg ttttttgtgt gtgcatttcc 600
attgttttcc ctcaatatag gtgcctattt cttctgaatc atattgacat tgcaaaccct 660
tttacgataa gatatttcat tgagcggata ctcttatccc gagctggcgg agggacaggc 720
cctatgaagc ccagcaaccg gtttctctgt tatttattat gttcaattga gtgagacaac 780
caagggtgcta acctgttgca aggttgatg attccttgag cgataagagt gaaaggcaca 840
aagaccaaac cctttcctcg atggaaaagg tttttttatt tcataaatat gccaatat 900
attctctaataaactgtac attgtataag agggagcag ttcctgatca tatatacaag 960
gtctttcggg aggccttgtg caggaggaag caaatc atg agt aaa aat cgt cgt 1014
Met Ser Lys Asn Arg Arg
1 5
tta ttt aca tca gaa tct gtt acg gag ggg cat ccg gat aaa atc tgt 1062
Leu Phe Thr Ser Glu Ser Val Thr Glu Gly His Pro Asp Lys Ile Cys
10 15 20
gac cag att tat gac agc att tta gat gaa att tta aag aaa gac cct 1110
Asp Gln Ile Tyr Asp Ser Ile Leu Asp Glu Ile Leu Lys Lys Asp Pro
25 30 35
aac gcg cgt gtt gct tgt gaa aca tct gtg aca aca ggt ttg gtt ctt 1158
Asn Ala Arg Val Ala Cys Glu Thr Ser Val Thr Thr Gly Leu Val Leu
40 45 50
gta agc gga gag atc aca act tct acg tat gtt gac att ccg aaa acg 1206
Val Ser Gly Glu Ile Thr Thr Ser Thr Tyr Val Asp Ile Pro Lys Thr

01-SQ Listing-31 Oct 2003.ST25.txt

55	60	65	70	
gtt cgc caa acc att aaa gaa atc gga tac aca cgt gca aaa tac gga val arg gln thr ile lys glu ile gly tyr thr arg ala lys tyr gly	75	80	85	1254
ttt gat gcg gaa act tgt gcg gtt tta aca tca att gat gag cag tct phe asp ala glu thr cys ala val leu thr ser ile asp glu gln ser	90	95	100	1302
gct gat atc gcg atg ggc gta gac cca gcg ctt gaa gcc cgt gaa ggc ala asp ile ala met gly val asp pro ala leu glu ala arg glu gly	105	110	115	1350
aca atg agc gac gaa gaa att gaa gcg att ggt gcg ggt gac caa gga thr met ser asp glu glu ile glu ala ile gly ala gly asp gln gly	120	125	130	1398
tta atg ttc ggt tat gtg tgc aac gaa acg aaa gag ctt atg cct ctt leu met phe gly tyr val cys asn glu thr lys glu leu met pro leu	135	140	145	1446
cca att tca ctt gcc cat aaa tta gcc cgc cgc cta agt gaa gtc cgt pro ile ser leu ala his lys leu ala arg arg leu ser glu val arg	155	160	165	1494
aaa gaa gat att ctt ccg tac ctt cgc cct gac ggc aaa aca cag gta lys glu asp ile leu pro tyr leu arg pro asp gly lys thr gln val	170	175	180	1542
acg gtt gag tac gat gaa aat aac aaa cca gtc cgc att gac gcg att thr val glu tyr asp glu asn asn lys pro val arg ile asp ala ile	185	190	195	1590
gtt att tca act cag cat cac cct gaa att aca ctt gag caa att cag val ile ser thr gln his his pro glu ile thr leu glu gln ile gln	200	205	210	1638
cgc aac att aaa gaa cat gta atc aat ccg gtt gtt cct gaa gag ctg arg asn ile lys glu his val ile asn pro val val pro glu glu leu	215	220	225	1686
att gat gaa gaa aca aaa tat ttc atc aac cct aca gga cgt ttc gta ile asp glu glu thr lys tyr phe ile asn pro thr gly arg phe val	235	240	245	1734
atc gga ggc cct caa ggg gat gcg gga ctt aca gga cgc aaa atc atc ile gly gly pro gln gly asp ala gly leu thr gly arg lys ile ile	250	255	260	1782
gtt gat acg tac ggc ggc tat gca cgc cac ggc gga ggc gcg ttc tca val asp thr tyr gly gly tyr ala arg his gly gly gly ala phe ser	265	270	275	1830
ggt aag gac gcg acg aag gta gac cgt tct gca gct tat gcg gca aga gly lys asp ala thr lys val asp arg ser ala ala tyr ala ala arg	280	285	290	1878
tac gtt gcg aaa aac atc gtt gcg gct gag ctt gct gat tct tgc gaa tyr val ala lys asn ile val ala ala glu leu ala asp ser cys glu	295	300	305	1926
gta cag ctt gct tac gcg atc ggt gtt gca cag cct gtg tca atc tca val gln leu ala tyr ala ile gly val ala gln pro val ser ile ser	315	320	325	1974
atc aac aca ttc ggt tca gga aaa gct tct gag gaa aaa ctg att gaa ile asn thr phe gly ser gly lys ala ser glu glu lys leu ile glu				2022

01-SQ Listing-31 Oct 2003.ST25.txt

330 335 340

gtt gtt cgc aat aac ttt gat tta cga cct gcc ggc att atc aaa atg 2070
 Val Val Arg Asn Asn Phe Asp Leu Arg Pro Ala Gly Ile Ile Lys Met
 345 350 355

ctt gat ttg cgc cgt ccg atc tat aaa caa act gct gcg tac ggc cac 2118
 Leu Asp Leu Arg Arg Pro Ile Tyr Lys Gln Thr Ala Ala Tyr Gly His
 360 365 370

ttt gga cgt cac gat gtt gac ctt cca tgg gag cgc aca gac aaa gcg 2166
 Phe Gly Arg His Asp Val Asp Leu Pro Trp Glu Arg Thr Asp Lys Ala
 375 380 385 390

gag cag ctg cgt aaa gaa gly lla gga gaa taa ttttatagcc gcttactggt 2219
 Glu Gln Leu Arg Lys Glu Ala Leu Gly Glu
 395 400

taagcggcct tccctttttt atcgttgrat tcatgtttat ttttttacat aactgcgaaa 2279

ccaaatacta ttacacagcgt ctataaatag gggttcaatg atgacaattt taattatgga 2339

ggcaatacta tgtgtggatt tgtcgggggtt tttacaagc atccgttagc tcaaaccgct 2399

gatcaagaag aactaatcaa acaaatgaac caaatgatcg ttcaccgcgg tcctgacagt 2459

gatggatatt tccatgatga gcacgtcggc ttcggattca gacggctcag cattattgat 2519

gtagaaaatg gtggacagcc tttatcatat gaagatgaaa catattggat tatctttaac 2579

ggagtaaatc ta 2591

<210> 17
 <211> 400
 <212> PRT
 <213> Bacillus subtilis
 <400> 17

Met Ser Lys Asn Arg Arg Leu Phe Thr Ser Glu Ser Val Thr Glu Gly
 1 5 10 15

His Pro Asp Lys Ile Cys Asp Gln Ile Tyr Asp Ser Ile Leu Asp Glu
 20 25 30

Ile Leu Lys Lys Asp Pro Asn Ala Arg Val Ala Cys Glu Thr Ser Val
 35 40 45

Thr Thr Gly Leu Val Leu Val Ser Gly Glu Ile Thr Thr Ser Thr Tyr
 50 55 60

Val Asp Ile Pro Lys Thr Val Arg Gln Thr Ile Lys Glu Ile Gly Tyr
 65 70 75 80

Thr Arg Ala Lys Tyr Gly Phe Asp Ala Glu Thr Cys Ala Val Leu Thr
 85 90 95

Ser Ile Asp Glu Gln Ser Ala Asp Ile Ala Met Gly Val Asp Pro Ala
 100 105 110

01-SQ Listing-31 Oct 2003.ST25.txt

Leu Glu Ala Arg Glu Gly Thr Met Ser Asp Glu Glu Ile Glu Ala Ile
 115 120 125

Gly Ala Gly Asp Gln Gly Leu Met Phe Gly Tyr Val Cys Asn Glu Thr
 130 135 140

Lys Glu Leu Met Pro Leu Pro Ile Ser Leu Ala His Lys Leu Ala Arg
 145 150 155 160

Arg Leu Ser Glu Val Arg Lys Glu Asp Ile Leu Pro Tyr Leu Arg Pro
 165 170 175

Asp Gly Lys Thr Gln Val Thr Val Glu Tyr Asp Glu Asn Asn Lys Pro
 180 185 190

Val Arg Ile Asp Ala Ile Val Ile Ser Thr Gln His His Pro Glu Ile
 195 200 205

Thr Leu Glu Gln Ile Gln Arg Asn Ile Lys Glu His Val Ile Asn Pro
 210 215 220

Val Val Pro Glu Glu Leu Ile Asp Glu Glu Thr Lys Tyr Phe Ile Asn
 225 230 235 240

Pro Thr Gly Arg Phe Val Ile Gly Gly Pro Gln Gly Asp Ala Gly Leu
 245 250 255

Thr Gly Arg Lys Ile Ile Val Asp Thr Tyr Gly Gly Tyr Ala Arg His
 260 265 270

Gly Gly Gly Ala Phe Ser Gly Lys Asp Ala Thr Lys Val Asp Arg Ser
 275 280 285

Ala Ala Tyr Ala Ala Arg Tyr Val Ala Lys Asn Ile Val Ala Ala Glu
 290 295 300

Leu Ala Asp Ser Cys Glu Val Gln Leu Ala Tyr Ala Ile Gly Val Ala
 305 310 315 320

Gln Pro Val Ser Ile Ser Ile Asn Thr Phe Gly Ser Gly Lys Ala Ser
 325 330 335

Glu Glu Lys Leu Ile Glu Val Val Arg Asn Asn Phe Asp Leu Arg Pro
 340 345 350

Ala Gly Ile Ile Lys Met Leu Asp Leu Arg Arg Pro Ile Tyr Lys Gln
 355 360 365

Thr Ala Ala Tyr Gly His Phe Gly Arg His Asp Val Asp Leu Pro Trp
 370 375 380

01-SQ Listing-31 Oct 2003.ST25.txt
Glu Arg Thr Asp Lys Ala Glu Gln Leu Arg Lys Glu Ala Leu Gly Glu
385 390 395 400